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Abstract 
Background: Diabetes mellitus is a chronic condition which is associated with serious 
microvascular and macrovascular complications and diminished quality of life. Intensive 
glycaemic control has been shown to reduce the incidence of diabetes-related 
complications in people with type 2 diabetes mellitus (T2DM) but can further decrease 
quality of life. Carbohydrate counting and flexible insulin dosing is known to improve 
glycaemic control and quality of life in adults with type 1 diabetes (T1DM). Limited 
evidence suggests that this diabetes management method can also reduce 
glycosylated haemoglobin (HbA1c) in people with type 2 diabetes (T2DM) using 
prandial insulin (Bergenstal et al., 2008) but this has not been investigated rigorously 
and no studies have investigated the impact on psychosocial outcomes. 
Research questions: Does insulin dose adjustment in line with mealtime carbohydrate 
intake in adults with T2DM using prandial insulin improve the primary outcomes HbA1c 
and quality of life? Impact on secondary outcomes including treatment satisfaction and 
vascular risk factors was also assessed. 
Method: A feasibility study, using a randomised controlled delayed start (waiting list) 
trial design, was conducted. Adults with T2DM using prandial insulin were trained to 
count carbohydrates and adjust insulin doses through group education sessions.  
Results: Carbohydrate counting and flexible insulin dosing in adults with T2DM was 
found to be non-inferior to static dosing insulin regimes, and was associated with 
improved quality of life and reduced perception of hypoglycaemia. This was associated 
with non-significant reductions in body weight, waist circumference and total daily 
insulin dose and was achieved despite increased dietary freedom, and without 
significant deterioration in other vascular risk factors. 
 
 
Conclusions: This management method has the potential to improve quality of life 
whilst maintaining or optimising glycaemic control in individuals with T2DM who require 
a variable insulin regime. The rising incidence of T2DM, its economic and health 
burden, and the increasingly younger patient profile make these findings particularly 
pertinent. Further research is warranted to explore these initial findings. 
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1. Introduction  
1.1 Impact of diabetes 
Diabetes mellitus (diabetes) is a condition of abnormal blood glucose regulation, 
usually considered life-long, affecting approximately 2.9 million people in the UK 
(Diabetes UK, 2012). The most prevalent variant of diabetes, type 2 diabetes (T2DM) is 
strongly associated with obesity (De Fronzo, 2004) and occurs as a result of failing 
pancreatic β-cell function, responsible for the production of insulin, and insulin 
resistance. This is in contrast to Type 1 diabetes (T1DM), an auto-immune disease 
resulting in the destruction of pancreatic β-cells. Both conditions cause loss of the 
ability to maintain normoglycaemia through relative or absolute insulin deficiency. 
Diabetes has significant implications for health and the economy in the UK. 
Hyperglycaemia, arising from inadequately controlled diabetes, is associated with the 
development of a number of pathologies including retinopathy, nephropathy, 
neuropathy and vascular disease. T2DM reduces life expectancy by up to 10 years, 
mainly due to increased cardiovascular disease (CVD) mortality (Roper, Bilous, Kelly, 
Unwin & Connolly, 2001). Diabetes is also associated with a reduction in quality of life 
(Holmes et al., 2000; Koopmanschap, 2002) and increased risk of depression 
(Jacobson, 1996).  Diabetes results in huge costs to the National Health Service (NHS) 
in the UK; £23.7billion was spent on the condition in the 2010/2011 financial year, 
approximately 10% of total NHS expenditure, with around 80% of the direct costs of 
diabetes going to treat complications (Hex, Bartlett, Wright, Taylor & Varley, 2012). It is 
well established that the greater the frequency and degree of hyperglycaemia, 
determined by glycosylated haemoglobin (HbA1c), the higher the risk of diabetes 
complications for both T1DM and T2DM (Diabetes Control and Complications Trial 
[DCCT], 1993; DCCT/Epidemiology of Diabetes Interventions and Complications 
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[EDIC] Study Research Group, 2005; Turner et al., 1998). It is therefore a priority in 
diabetes management to achieve well-controlled blood glucose levels using drug 
therapy and lifestyle advice. 
1.2 Management of type 2 diabetes 
A large number of pharmacological therapies for the management of blood glucose 
levels in T2DM exist however the progressive nature of T2DM results in the eventual 
requirement of insulin treatment in many individuals. Carbohydrate counting and 
flexible insulin dosing as a diabetes management technique for T1DM has been shown 
to improve glycaemic control and quality of life (Dose Adjustment for Normal Eating 
[DAFNE] Study Group, 2002) and is advocated in the UK due to its clinical and cost-
effectiveness (National Institute for Health and Clinical Effectiveness [NICE], 2003; 
NICE, 2004). This method of matching prandial insulin doses to blood glucose levels, 
predicted through assessment of mealtime carbohydrate intake, instead of adhering to 
static insulin doses, may aid glycaemic control in T2DM (Bergenstal et al., 2008) but its 
use is under-researched. Carbohydrate counting and flexible insulin dosing has the 
potential to improve clinical and patient outcomes in T2DM and its impact should be 
thoroughly assessed.  
1.3 The research project 
The following feasibility study was designed to assess the effect of educating adults 
with T2DM in carbohydrate counting and insulin dose adjustment techniques. This 
report explores the impact of diabetes in more detail, looks at current treatment options 
for T2DM and assesses the evidence for and against carbohydrate counting and 
flexible insulin dosing in this group. It describes the methodology and presents results 
of this study with reference to the effect on glycaemic control, psychosocial outcomes 
and vascular risk factors, discussing their relevance with regard to current literature. 
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2. Literature review 
The following literature review investigates in more depth the basis for 
recommendations on glycaemic control in diabetes and the impact of diabetes on 
quality of life. It spans current treatment options in T2DM and discusses both the 
background to carbohydrate counting and insulin dose adjustment and its use in T2DM.  
2.1 Glycaemic control in type 2 diabetes  
2.1.1 Microvascular and macrovascular complications in 
diabetes 
T1DM and T2DM are both associated with an increased risk of development of 
microvascular and macrovascular pathologies including cardiovascular disease (CVD), 
peripheral vascular disease, nephropathy, neuropathy and retinopathy (Skyler et al., 
2009). Large landmark studies in the 1990s clearly showed for the first time that 
maintaining blood glucose levels close to the non-diabetic range prevented, delayed or 
slowed the progression of diabetes-related complications in both T1DM and T2DM 
(Diabetes Control and Complications Trial [DCCT], 1993; Turner et al., 1998). Both 
studies resulted in a change in clinical practice but were unable to show a reduction in 
macrovascular risk.  
Evidence that good glycaemic control reduces the risk of the macrovascular 
complications myocardial infarction, stroke and death from CVD in T1DM came with 
the later study, a long term follow-up of the DCCT cohort, the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study (DCCT/EDIC Study Research Group, 
2005). Evidence from three large well designed studies in adults with T2DM since then 
has challenged the idea that macrovascular disease risk in T2DM is reduced with 
improved glycaemic control. The three studies, the Veterans Affairs Diabetes Trial 
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(VADT), Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and the 
Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE) study all showed no reduction in CVD events in 
intensive treatment groups compared to conventional treatment (ACCORD Study 
Group, 2008; ADVANCE Collaborative Group 2008; Duckworth et al., 2009). In 
contrast the STENO-2 study showed a 50% CVD risk reduction in T2DM with intensive 
therapy for glycaemic control, blood pressure, lipids and lifestyle (Gæde et al., 2003) 
although CVD risk reduction due to glycaemic control alone was not analysed. This is 
further complicated by the ACCORD study being prematurely terminated due to a 
higher mortality rate in the intensively treated group; however there was a trend 
towards lower incidence of cardiovascular events in some subgroups, leaving the 
possibility of benefit in intensive control on macrovascular disease risk in certain 
individuals with T2DM open. 
The reason for the increased all-cause and cardiovascular mortality rate in the 
ACCORD study is unknown. Possible factors may have included the magnitude, or 
rate, of decrease of HbA1c, or the incidence of hypoglycaemia (Dluhy & McMahon, 
2008). Hypoglycaemia has been linked to increased mortality by inducing cardiac 
arrhythmias and causing sudden death in both T1DM and T2DM (Heller, 2008; 
Lindström, Jorfeldt, Tegler & Arnqvist, 1992). As increased body mass index (BMI) and 
waist circumference are associated with increased CVD risk (Dobbelsteyn, Joffres, 
MacLean & Flowerdew, 2001; Wilson, D'Agostino, Sullivan, Parise & Kannel, 2002), 
decreases in cardiovascular risk in the ACCORD and VADT study may also have been 
negated by the weight gain occurring as a result of intensive control (Skyler et al., 
2009). Whilst definitive evidence of the benefits of intensive glycaemic control on 
macrovascular outcomes in T2DM is lacking, the risk reduction of microvascular 
complications is well established. It is evident that treatments to optimise glycaemic 
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control in diabetes are vital but should not achieve this aim at the expense of weight 
gain or hypoglycaemia. 
2.1.2 Glycaemic targets 
Glycaemic targets for adults with T2DM should be personalised with reference to 
individual lifestyle and medical history but where possible, adherence to the national 
HbA1c target of 48mmol/mol should be promoted (NICE, 2009). In England in 2010-
2011 only 26.4% of individuals with T2DM achieved HbA1c <48mmol/mol, and only 
66.5% achieved HbA1c ≤58mmol/mol (Health and Social Care Information Centre, 
2012) indicating considerable room for improvement. However the practice of 
monitoring targets in this way has been questioned as it does not allow for 
individualisation of glycaemic goals (Inzucchi et al., 2012). Achievement of glycaemic 
targets, individual or national, is challenging for many reasons and adults with T2DM 
may struggle with barriers to attaining their target including hypoglycaemia, prohibitive 
diet and lifestyle advice, side-effects of treatments and lack of knowledge and 
motivation.  
2.2 Quality of life in diabetes 
Quality of life (QoL) is a subjective perception of an individual’s own physical, 
emotional and social well-being and is both difficult to define and difficult to measure. In 
recent years health-related quality of life (HRQoL), the quality of life determined by the 
presence and management of medical conditions, has become an increasingly 
important concept, considered by some to be our single most important clinical and 
research outcome (Polonsky, 2000) and the ultimate aim of all healthcare interventions 
(Rubin & Pevrot, 1999). Accordingly quality of life, not just length of life, is used to 
determine the cost-effectiveness of new treatments by NICE through the use of 
Quality-Adjusted Life Years (QALYs) (NICE, 2010).  
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QoL can be profoundly affected by T2DM in several ways. It is lower in individuals with 
T2DM compared to age-matched individuals without the disease (Holmes et al., 2000) 
and further declines with the onset of diabetes-related complications (Koopmanschap, 
2002; Solli, Stavem & Kristiansen, 2010; Wexlar et al., 2006). It is unclear whether use 
of insulin in T2DM reduces QoL, with some research supporting (Koopmanschap, 
2002) and other research refuting the idea (Pibernik-Okanoviæ, Szabo & Melko, 1998; 
Wandell, Brorsson & Åberg, 1998; Wexlar et al. 2006). It may be that insulin use acts 
as a proxy measure for disease progression and presence of diabetes complications, 
and when controlled for, the association with QoL diminishes (Wandell at al., 1998; 
Wexlar et al., 2006). Moreover use of insulin and improved glycaemic control can both 
result in greater frequency of hypoglycaemia (Wright et al., 1998), fear of which 
negatively impacts QoL in type 2 diabetes (Solli et al., 2010), although this has a small 
effect relative to the QoL decrement induced by diabetes-related complications (Matza 
et al., 2007). This is manifest in research showing a lower HbA1c does not improve 
QoL (Maddigan, Feeny, & Johnson, 2004; Wexlar et al., 2006) although this is not 
supported by all evidence (Lau, Qureshi, & Scott, 2004). The discordance in these 
results is perhaps attributable to the varying burden of hypoglycaemia within the two 
populations. This demonstrates that patients and clinicians can have the opposing 
goals of present quality of life versus optimal glycaemic control and future health; 
finding treatments that allow convergence of these goals is an unequivocal aim of 
research. 
 
2.3 Pharmacological and lifestyle management of type 2 
diabetes  
T2DM is caused by the interaction of a number of genetic and environmental factors. It 
is estimated that approximately 80% of T2DM incidence is due to the metabolic 
10 
 
consequences of obesity (Gregg, Cheng, Narayan, Thompson, & Williamson, 2007). 
Consequently glycaemic control and risk of diabetes complications can be improved as 
a result of intentional weight loss in T2DM (Bosello, Armellini, Zamboni & Fitchet, 1997; 
Williamson et al., 2000). Furthermore remission of T2DM is a well-established result of 
bariatric surgery, although the mechanism appears not to be due to weight loss alone 
(Sala, Torrinhas, Heymsfield, & Waitzberg, 2012). It may also be possible to reverse 
T2DM through weight loss induced by severe dietary energy restriction without surgery 
(Lim et al., 2011). It is beyond the scope of this discussion to explore the literature on 
weight loss interventions in T2DM but it is recognised that a successful way to manage 
T2DM in many individuals would be weight loss (Nathan et al., 2009; NICE, 2009). 
Unfortunately with even the most efficacious multifactorial interventions, weight loss 
results are generally modest at best (NICE, 2006); bariatric surgery has a more 
profound effect on body weight and a predictable remission rate for T2DM (Buchwald 
et al., 2009) however is not suitable for many individuals. Pharmacological methods of 
managing T2DM will therefore be required until more effective methods of eliciting and 
maintaining weight loss are available, and for those individuals with significant 
pancreatic β-cell dysfunction. 
There are a multitude of hypoglycaemic agents available for T2DM but as the disease 
progresses it becomes increasingly difficult to achieve good glycaemic control. 
Pancreatic β-cell function deteriorates at a rate of approximately 3-4% a year and many 
individuals with T2DM eventually require insulin replacement therapy (Wright et al., 
1998).  The optimal insulin regime for T2DM is not established and depends heavily on 
the individual’s circumstances (NICE, 2009). Any insulin therapy will benefit an insulin-
naïve adult with T2DM and poor glycaemic control (Holman et al., 2009) but if ill-
matched to their lifestyle, and without sufficient education, insulin initiation can risk 
weight gain and hypo- or hyperglycaemia (Inzucchi, et al., 2012).  Young adults can 
have significant variability in meal timing, frequency and content (Huang, Song, 
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Schemmel & Hoerr, 1994) therefore insulin management methods suited to dealing 
with this type of lifestyle are required to respond to the increasing prevalence of T2DM 
in younger age groups (Fox et al., 2006; Pinhas-Hamiel & Zeitler, 2005) and the 
serious mortality and morbidity resulting from poorly controlled diabetes. Basal-bolus 
insulin therapy, a combination of peak-less background insulin plus boluses of rapid-
acting prandial doses, is closest to the physiological provision of insulin (Franc et al., 
2009) and facilitates a higher degree of insulin adaptability. In addition, basal-bolus 
insulin therapy could be coupled with carbohydrate counting and insulin dose 
adjustment, described below, potentially providing the greater flexibility required.  
2.4 Carbohydrate counting and insulin dose adjustment 
Carbohydrate counting and insulin dose adjustment (or simply “carbohydrate counting”) 
employs knowledge of the macronutrient content of food to predict post-prandial blood 
glucose levels. It enables the user to calculate the most appropriate insulin dose for 
any meal, plus a corrective insulin dose for out-of-target blood glucose levels and 
accommodation of physical activity, instead of adhering to a static insulin dosing 
regime. Individuals on a basal-bolus insulin regime use this method of diabetes 
management by maintaining background insulin at a fairly static dose whilst quick-
acting prandial insulin is titrated in accordance with glycaemia and carbohydrate intake, 
through use of insulin-to-carbohydrate ratios.  
Carbohydrate counting allows the user to separate the decisions about healthy eating 
and insulin requirements, with the aim being good glycaemic control regardless of 
frequency and composition of meals (Heller et al., 2002). This is not currently an 
established management method for T2DM on basal-bolus insulin in the UK, meaning 
many individuals with T2DM either adhere to a rigid dosing regime, or alter their insulin 
doses based on experience, total quantity of food and/or blood glucose levels. Recent 
Diabetes UK guidelines for the management of T2DM concluded that the efficacy of 
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carbohydrate counting in insulin-treated T2DM is largely unknown (Dyson et al., 2011) 
reflecting a lack of research, rather than evidence of ineffectiveness.  
The carbohydrate, protein and fat content of a meal, the glycaemic index of the 
carbohydrate, the time of day and a variety of other factors can affect post-prandial 
blood glucose levels, but carbohydrate load is the strongest predictor of the glycaemic 
response to a meal (Sheard et al., 2004). Carbohydrates cause 47-56% of the post-
meal variation in glycaemia (Wolever & Bolognesi, 1996) and almost 100% of the 
carbohydrate within a meal is converted to glucose within 90 minutes (Laine, Thomas, 
Levitt & Bantle 1987). Within the majority of the physiological range there is a linear 
relationship between carbohydrate intake and insulin requirements (Halfon, Belkhadir & 
Slama, 1989) indicating post-meal insulin requirements can be estimated from the 
carbohydrate load of a meal. This led to the development of carbohydrate counting and 
insulin dose adjustment as a method of controlling blood glucose levels by mimicking 
endogenous insulin production in response to carbohydrate loads.  
Algorithms advocating carbohydrate, protein and fat counting have been proposed to 
approximate insulin requirements (Howorka, Thoma, Grillmayr, & Kitzler, 1990), but 
only carbohydrate counting has been widely adopted and evidence suggests protein 
and fat counting algorithms are less effective (Franc et al., 2009). Carbohydrate 
counting and flexible insulin dosing is well established as an effective management 
method for T1DM (DAFNE Study Group, 2002; Laurenzi et al., 2011; Mehta, Quinn, 
Volkening, & Laffel, 2009; Mühlhauser et al., 1983) and has also been deemed cost-
effective despite increased healthcare professional contact time during education 
(NICE, 2003). The seminal research investigating this technique in T1DM in the UK 
was the DAFNE (Dose Adjustment For Normal Eating) study. Educating participants in 
this method of diabetes management resulted in a drop in HbA1c of approximately 
11mmol/mol, a reduction in severe hypoglycaemia and an improvement in quality of life 
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(DAFNE Study Group, 2002).  Long term follow-up showed attrition in the improvement 
in HbA1c, yet quality of life remained significantly improved from baseline, even at four 
years post education (Speight et al., 2010). 
2.5 Carbohydrate counting and insulin dose 
adjustment in type 2 diabetes 
Although bearing similarities, T1DM and T2DM are diseases with very different 
aetiologies. The following discussion explores the suitability of carbohydrate counting 
and insulin dose adjustment in the context of T2DM physiology. 
The pathogenesis of T2DM is complex and not fully understood. It appears to begin 
with a period during which endogenous insulin production is elevated to overcome 
hepatic insulin resistance (resulting in inappropriate gluconeogenesis and 
glycogenolysis and therefore elevated fasting plasma glucose) and reduced muscle 
insulin sensitivity (Taylor, 2008). Hyperinsulinaemia may result in normoglycaemia for a 
time until pancreatic β-cell function deteriorates, at which point overt diabetes can be 
identified. Pre-existing β-cell secretory dysfunction, identifiable in individuals with 
normal glucose tolerance and insulin sensitivity but genetically predisposed to T2DM, is 
also implicated in the development of T2DM (Alsahli & Gerich, 2010). Insulin 
production typically has an inverse relationship with time since diagnosis and the 
eventual decline of β-cell function necessitates insulin therapy initiation (DeFronzo, 
2004).  
An individual with T2DM remains biologically different to a person with T1DM despite a 
potentially identical therapeutic intervention. In T1DM endogenous insulin is minimal or 
absent (Atkinson & Eisenbarth, 2001) whilst in insulin-treated T2DM some insulin 
production ability is usually retained, albeit impaired (Taylor, 2008). This indicates that 
excursions from normoglycaemia may be greater in T1DM. In addition the 
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counterregulatory hormone response to hypoglycaemia which is lost in T1DM is at 
least partly preserved in T2DM offering a greater degree of protection against 
hypoglycaemia (Zammitt & Frier, 2005). Nevertheless a similarity between T1DM and 
T2DM is the inability to raise a post-prandial insulin response. Although there will be 
some endogenous insulin contribution in T2DM, it would be expected that individuals 
with T2DM would require higher insulin-to-carbohydrate ratios and have lower insulin 
sensitivity than T1DM as a result of the insulin resistance inherent in T2DM. Whether in 
a state of relative insulin deficiency, as in T2DM, or absolute insulin deficiency, as in 
T1DM, mealtime insulin requirements are determined by pre-prandial blood glucose 
levels plus post-prandial hyperglycaemia, the latter of which can be reliably predicted 
by carbohydrate counting. 
It is surprising, considering the success of carbohydrate counting and flexible insulin 
dosing in T1DM and the physiological plausibility of using this method in T2DM, that 
there is a paucity of literature exploring the use of this technique in people with T2DM. 
This could be due to apprehension that the increased dietary freedom enabled by 
insulin dose adjustment would be detrimental to body weight and CVD risk factors, or 
that little would be gained in terms of glycaemic control due to the physiological 
differences outlines above. A small number of studies exist that suggest the potential 
success of carbohydrate counting in T2DM, and notably no studies indicate it is 
ineffective, although positive publishing bias cannot be discounted. A review of the 
current literature on carbohydrate counting in T2DM follows. 
Good quality evidence for individuals with T2DM on basal-bolus insulin using 
carbohydrate counting and insulin dose adjustment amounts to one study. In a 
randomised controlled trial including 273 participants, Bergenstal et al. (2008) indicated 
that carbohydrate counting could be an effective method of glycaemic control in T2DM. 
They demonstrated no difference in HbA1c reduction between carbohydrate counting 
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and insulin dose adjustment, and using a simple algorithm method based on 3 day 
averages of blood glucose levels, to control glycaemia in a group of adults with T2DM. 
The average HbA1c in the carbohydrate counting group at the end of the 24 week 
study period was 48mmol/mol compared to 50mmol/mol in the algorithm group. The 
equality of success of the techniques is perhaps surprising presuming variability in 
mealtime carbohydrate intake in both groups and the authors acknowledge it is 
possible participants in the algorithm group had a more standardised carbohydrate 
intake, or that they adjusted their carbohydrate intake to suit their insulin doses, both of 
which would have resulted in an improved HbA1c in conjunction with the algorithm 
method. At the end of the study total daily insulin doses were significantly lower and 
there was a trend towards less weight gain in the carbohydrate counting group. 
Incidence of hypoglycaemia with blood glucose levels <4.0mmol/l did not differ 
between groups but hypoglycaemia with blood glucose levels <2.8mmol/l was more 
common in the carbohydrate counting group.  
Further evidence includes Zipp, Roehr, Weiss and Filipetto’s (2011) small scale pilot 
study of just six participants, four of whom completed the carbohydrate counting 
training. Results suggested an improvement in HbA1c with participants stating they felt 
an increased sense of ability to manage their diabetes (statistical analyses were not 
performed). Unfortunately this study involved too few participants be able to deliver 
reliable conclusions and included participants on both insulin therapy and oral 
medication meaning the results are not transferable to a population of individuals on 
basal-bolus insulin therapy. It is also too disparate a group for a HbA1c change to 
represent a meaningful clinical improvement. In a slightly larger participant cohort, Rizvi 
(2005) showed a reduction in HbA1c from 72mmol/mol to 53mmol/mol for 17 patients 
with T2DM who were transferred from ineffective oral and/or insulin therapy to a basal-
bolus insulin regime with education including carbohydrate counting. However this 
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study included no control group and improvements in glycaemic control may have 
derived from the change in pharmacological therapy alone.  
More recently, when investigating efficacy of insulin pump therapy in T2DM, Leinung, 
Thompson, Luo, Leykina and Nardacci (2012) found that use of carbohydrate counting 
and prandial insulin calculator software was not superior to a static dose regime. This 
retrospective study only included a small number of participants and all individuals 
were taught to carbohydrate count prior to receiving a pump therefore, even if this 
management technique was not actively used, all participants were carbohydrate-
aware. Due to lack of randomisation, the participants in the carbohydrate counting 
group had a higher mean baseline HbA1c, and a slightly higher HbA1c at 6 months 
meaning glycaemic control results were difficult to interpret. Furthermore, the 
distinction between individuals who were carbohydrate counting and those using static 
doses was based on the most frequent bolus dosing method, static or adjusted, and 
there may have been considerable overlap of use of methods between groups. It 
cannot be concluded with certainty whether carbohydrate counting was beneficial in 
adults with T2DM on insulin pumps.  
In conclusion, carbohydrate counting and insulin dose adjustment in T2DM is an under-
researched area, particularly with regard to its impact on psychosocial outcomes which 
have not been examined at all. With its success in T1DM, carbohydrate counting and 
insulin dose adjustment is a good candidate to explore for the management of T2DM.  
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2.6 Summary of literature 
Adults with T2DM are vulnerable to increased mortality and morbidity, and diminished 
health-related quality of life arising from their condition. Treatments to improve 
glycaemic control can result in further decrements in QoL. Despite many developments 
in diabetes care, there is still certainly potential to offer treatments that more effectively 
enable achievement of individual glycaemic targets whilst minimising impact on QoL. 
Given the proven effectiveness of carbohydrate counting and flexible insulin dosing in 
T1DM, both in improving glycaemic control and QoL, and the potential value of offering 
individuals with T2DM on basal-bolus insulin greater flexibility than conventional 
treatments, studies to investigate its impact on HbA1c and QoL are clearly warranted. 
This feasibility study will explore the effect of insulin dose adjustment in line with 
mealtime carbohydrate intake on biomedical and psychosocial parameters in adults 
with T2DM and could inform further research with the potential to enhance the future 
management of adults with T2DM. 
2.7  The research questions 
2.7.1 Aim of project 
The aim of the research was to evaluate the impact of training in carbohydrate counting 
and insulin dose adjustment on biomedical and psychosocial outcomes in adults with 
T2DM on a basal-bolus insulin regime.  
2.7.2 Primary research question 
Does carbohydrate counting and flexible insulin dosing affect HbA1c or QoL in adults 
with T2DM on a basal-bolus insulin regime? 
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Primary outcomes: HbA1c and QoL questionnaire 
Null hypotheses:  
 Carbohydrate counting and flexible insulin dosing does not affect HbA1c 
 Carbohydrate counting and flexible insulin dosing does not affect QoL 
2.7.3 Secondary research question 
Does carbohydrate counting and flexible insulin dosing affect proportion of patients 
achieving HbA1c <53mmol/mol, incidence of hypoglycaemia, total daily insulin doses 
(TDI), general well-being, treatment satisfaction or vascular disease risk factors in 
adults with T2DM on a basal-bolus insulin regime? 
Secondary outcomes: Self-reported incidence of hypoglycaemia and TDI, general 
well-being and treatment satisfaction questionnaires, BMI, waist circumference, blood 
pressure and lipid profile 
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3.  Methods 
3.1 Study design 
This original quantitative research was a yearlong feasibility study examining the 
impact of the educational intervention MATCH IT (MAtching Treatment to 
CarboHydrate in Insulin-treated type Two diabetes) designed to teach carbohydrate 
counting and insulin dose adjustment to adults with T2DM on basal-bolus insulin. A 
pilot randomised delayed start (waiting list) trial design was used to investigate the 
dependent variables glycaemic control, quality of life and vascular risk factors, whilst 
manipulating the independent variable carbohydrate counting and insulin dose 
adjustment training and observing confounding factors physical activity levels and 
alcohol intake. Participants were randomly split into 2 groups, one group receiving the 
educational intervention at baseline, the immediate intervention group (Group I), and 
the other receiving it 6 months after baseline, the delayed intervention group (Group 
D). For the first six months participants allocated to the delayed intervention group 
acted as a control group by continuing to receive standard care, which included any 
appointments with clinicians already planned, and continuing with usual insulin doses 
and dose adjustments. The design was based on a study involving flexible insulin 
management in people with type 1 diabetes (DAFNE Study Group, 2002).  
3.1.1 Ethical approval 
This study was granted ethical approval from the North West 1 Research Ethics 
Committee (Cheshire) on 12th November 2010 (Appendix 1) and was accepted by the 
Countess of Chester Hospital NHS Foundation Trust Research and Development 
Department. Sponsorship was provided jointly by the University of Chester and the 
Countess of Chester Hospital NHS Foundation Trust (Appendix 2). 
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Ethical approval was also granted for analyses of data regarding insulin-to-
carbohydrate ratios and adiposity but this was later acknowledged to be beyond the 
scope of this thesis. 
3.1.2 Dependent variables 
3.1.2.1 HbA1c and lipid profile 
Non-fasting blood samples were obtained by phlebotomy staff at the Countess of 
Chester Hospital and analysed in the on-site laboratory to provide HbA1c and lipid 
profile data including total cholesterol (TC), high density lipoprotein (HDL) cholesterol 
and triglycerides. HbA1c was reported in IFCC (International Federation of Clinical 
Chemistry) units. 
3.1.2.2 Anthropometry 
Height was measured using a Seca stadiometer; measurements were recorded to the 
nearest 0.1cm. Weight was measured using Seca scales (calibrated annually) and 
recorded to the nearest 0.1kg. Waist circumference was measured to the nearest 
0.5cm in accordance with international guidelines (World Health Organisation [WHO], 
2011) using a tape measure placed midway between the lowest palpable rib and the 
top of the iliac crest. 
3.1.2.3 Blood pressure 
Systolic and diastolic blood pressure was measured using a Welch Allyn digital 
sphygmomanometer (calibrated annually). 
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3.1.2.4 Insulin doses, hypoglycaemia, medical & drug 
history and lifestyle 
A researcher-administered questionnaire (Appendix 3) was used to collect insulin dose 
and hypoglycaemia information. Total daily insulin doses (TDI) were collected as 
patient-reported average doses. Incidence and severity of hypoglycaemia was 
recorded as patient-reported average number of hypoglycaemic episodes per month; 
severity classification was based on American Diabetes Association Workgroup on 
Hypoglycaemia (2005) definitions for hypoglycaemia. Medical and drug history and 
lifestyle information was gathered to monitor as confounding factors and for eligibility. 
Physical activity level was measured subjectively using patient-reported grade of 
sedentary, light, moderate, or intensive with a standardised definition given by 
researcher. Alcohol intake was recorded as patient-reported average units per week.  
3.1.2.5 Questionnaires 
The Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire, Diabetes 
Treatment Satisfaction Questionnaire (DTSQ), Diabetes Treatment Satisfaction 
Questionnaire - change (DTSQc) and Well-Being Questionnaire (W-BQ12) (Appendix 
4) were obtained from Health Psychology Research Ltd with an approved licence 
application (Appendix 5).  
The ADDQoL questionnaire was used three times throughout the study - at baseline, 
six and twelve months. This questionnaire was developed for use specifically in 
diabetes (Bradley et al., 1999) and has subsequently been improved, the most up-to-
date version being used as part of this research (Wee, Tan, Goh & Li, 2006).  It is 
designed to capture the effect of diabetes on nineteen different aspects of quality of 
life, including dietary freedom, and allows weighting of scores according to importance 
for the subject. For example a participant might report that diabetes has a large 
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negative effect on their financial circumstances but if finances are not important to them 
then this will provide a low weighted score. Combining all weighted scores generates 
an average weighted impact (AWI) score indicative of overall effect of diabetes on all 
aspects of quality of life considered. In addition it provides two overview question 
scores on general present quality of life and quality of life as affected by diabetes.   
The DTSQ questionnaire (Bradley, 1994) assesses current satisfaction with treatment 
through six questions and the DTSQ (change) questionnaire (Bradley et al., 2000) 
determines how participants’ satisfaction with their treatment is different compared to 
their previous treatment. In addition both assess perceived frequency of hypoglycaemia 
and hyperglycaemia. The DTSQ was used three times throughout the study, at 
baseline, six and twelve months, whilst the DTSQc was used only once, 6 months after 
the educational intervention (at 6 months for the intervention group and at 12 months 
for the delayed intervention group) to compare satisfaction with the management 
method taught by MATCH IT to their previous static insulin dose regime. A revision to 
the text of the two questionnaires was employed to clarify their use with regard to the 
current study.  
The W-BQ12 is designed to assess twelve aspects of positive and negative well-being 
which are combined to provide a general well-being score (Bradley and Lewis, 1990; 
Riazi et al., 2006) and was used at baseline, six and twelve months. Together with the 
DTSQ, these questionnaires have been advocated by the World Health Organisation 
(WHO) and International Diabetes Federation (IDF) as tools to monitor psychological 
outcomes in diabetes care (Bradley & Gamsu, 1994). 
All three questionnaires have been validated in adults with diabetes (Wee, Tan, Goh & 
Li, 2006; Pouwer, Snoek, & Heine, 1998; Pouwer, van der Ploeg, Adèr, Heine & Snoek, 
1999) and have proven sensitive to changing from a rigid to a flexible insulin regime 
(DAFNE Study Group, 2002). Scoring of the questionnaires and treatment of missing 
23 
 
data followed questionnaire guidance (Bradley, 2010a; Bradley 2010b; Bradley 2010c; 
Bradley 2010c). 
3.2 Population and subjects 
3.2.1 Sample and sample size estimation 
Data did not exist to allow a meaningful sample size calculation for this feasibility study 
but a sample size was estimated using G*Power software version 3.1.2 (Buchner, 
Erdfelder, Faul & Lang, 2009).  
Based on results from the DAFNE study, the effect size of the intervention was d=0.79 
for a 10mmol/mol drop in HbA1c and d=0.86 for a 63% improvement in the ADDQoL 
question regarding dietary freedom in the DAFNE arm. To detect a 10mmol/mol drop in 
HbA1c in the intervention group with 80% power (p<0.05, two-tailed), 27 participants in 
each arm were required. To detect a 63% improvement in sense of dietary freedom in 
the intervention group with 80% power (p<0.05, two-tailed), 23 participants in each arm 
were required.  
As this study has more than one primary outcome, as is common in modern clinical 
trials, the sample size should be sufficient to detect differences in both the outcomes 
hence a sample size of at least 27 participants in each arm would be required. It is 
possible that effect size of this intervention would be smaller in a sample of adults with 
T2DM, meaning the required sample size is here underestimated. However the size of 
the sample for this feasibility study had to be pragmatically based on the minimum 
number of participants to make the study design viable, which was estimated at 8 in 
each arm, and the maximum number that would be manageable given the constraints 
of the time and resources of a Masters project and the limited eligible population in the 
Cheshire area, estimated at 15 participants in each arm.  
24 
 
 
3.2.2 Population and recruitment 
Suitable potential participants, adults with T2DM on basal bolus insulin from the 
Countess of Chester Hospital NHS Foundation Trust Diabetes Unit, were identified by 
a computerised search of Countess of Chester Hospital electronic medical records. 
This was carried out using relevant search terms including type 2 diabetes and prandial 
insulin brand names. The records searched were those created by diabetes doctors 
during annual review appointments at the Diabetes Centre. Potential participants’ 
electronic medical records were then manually checked for eligibility. In addition the 
diabetes team were informed of the eligibility criteria for the study and opportunistically 
recruited participants from clinic appointments. Potential participants were invited into 
the study by letter (Appendix 6) and telephone calls.  
3.2.3 Eligibility criteria 
3.2.3.1    Inclusion criteria 
 Male or female aged 18 years+ with type 2 diabetes  
 Self-administering prandial insulin at least twice daily, with or without long-
acting insulin, for at least 6 months. 
 If taking metformin, stable dose for 3 months prior to study. 
 Willingness to learn carbohydrate counting and flexible insulin dosing 
management methods and adhere to study procedures. 
 Deemed medically suitable to participate by consultant diabetologist at 
Countess of Chester Hospital 
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3.2.3.2  Exclusion criteria 
 Acute illness. 
 Inability to communicate in spoken and written English. 
 Pregnancy.  
 Lack of awareness of hypoglycaemia. 
 Use of anti-diabetic medication except metformin. 
3.2.4 Consent 
The research was discussed with potential participants over the telephone and in 
person, and a Participant Information Sheet (Appendix 7) was provided at least one 
week prior to the first appointment.  Written informed consent was gained using the 
study Consent Form (Appendix 8) at the first appointment, prior to commencing any 
study procedures. 
3.2.5 Participant reimbursement 
Participants received reimbursement for travel expenses and parking costs incurred as 
a result of complying with study procedures which was funded through grant monies 
awarded by Sanofi-Aventis for this project. 
3.3 Procedures 
All study procedures were carried out by the author of this thesis who is a registered 
dietitian. In line with specialist diabetes service provision recommendations (Goenka, 
Turner & Vora, 2011), local agreements are in place at the Countess of Chester 
Hospital NHS Foundation Trust permitting competent Diabetes Specialist Dietitians to 
support and advise patients on insulin dose adjustment. 
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3.3.1 Randomisation 
Participants and the researcher were not blinded to treatment allocation. Participants 
were randomised into either Group I or Group D using a permuted block method with a 
random number sequence generated by Random.org (Haahr & Haahr, 1998) to ensure 
equal numbers of participants in each group. Group allocations were written down and 
placed in opaque envelopes by a member of staff not involved in the research. At the 
end of each initial data collection appointment, after consent was obtained, the 
envelopes were opened in order and participants informed of their group assignment.  
3.3.2 Study procedure 
All study visits took place in the Countess of Chester Hospital Diabetes Unit. Figure 1 
outlines study procedures. Group I commenced MATCH IT less than 2 weeks after the 
baseline data collection visit and Group D commenced MATCH IT less than 2 weeks 
after the six month data collection visit. 
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Participant confirms provisional 
interest in study and Participant 
Information Sheet and consent form is 
posted to be read prior to Visit 1 
 
 
Visit 1: Baseline - Written informed 
consent obtained and data collection 
appointment 
 
MATCH IT education course plus 
individual review then return to 
standard care 
 
 
Continue with standard care 
 
Visit 2: 6 months – data collection 
appointment 
 
Visit 2: 6 months – data collection 
appointment 
 
Continue with standard care 
 
MATCH IT education course plus 
individual review then return to 
standard care 
 
Visit 3: 12 months – data collection 
appointment 
 
Visit 3: 12 months – data collection 
appointment 
 
Randomisation 
50% participants 
 
50% participants 
 
Figure 1 Flowchart indicating study procedures 
 
Potential participants contacted by 
letter and telephone calls 
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3.3.3 MATCH IT 
The educational intervention MATCH IT (MAtching Treatment to CarboHydrate in 
Insulin-treated type Two diabetes) comprised two half-day group education sessions on 
two consecutive weeks at the Countess of Chester Hospital, followed by an individual 
review appointment. If additional support was required after the MATCH IT course, this 
was provided as part of the routine care offered by the team at the Diabetes Centre in 
the hospital.  
The MATCH IT course content and resources were developed specifically for the study  
and were based on an existing successful carbohydrate counting and insulin dose 
adjustment course for T1DM at the Countess of Chester Hospital (Patel et al., 2010) 
and Diabetes UK workbooks (Diabetes UK, 2008). MATCH IT was delivered by a 
Diabetes Specialist Dietitian, the author of this thesis, with a focus on improving 
glycaemic control and facilitating dietary flexibility through carbohydrate counting and 
insulin dose adjustment. Glycaemic targets of 4.0-7.0 mmol/l pre-meal and 2 hours 
post-prandial <8.5mmol/l were recommended as per national guidance (NICE, 2009). 
Personalised insulin-to-carbohydrate portion (insulin:CP) ratios and correction factors 
were calculated directly from participants’ blood glucose and food diaries (calculations 
provided in Appendix 9). Four MATCH IT courses ran in total, two for each arm, with 
five participants in each. The MATCH IT education sessions were standardised by 
using a defined lesson plan and presentation ensuring consistent reproducibility. The 
course content is outlined in Figure 2; a course manual was provided to support 
learning. Participants’ GPs were informed by letter of their contribution to the research 
(Appendix 10). 
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Day one 
 Identification of carbohydrates  
 Concept of the "carbohydrate portion" or CP which equates to 10-12g 
carbohydrate 
 Calculation of CPs consumed per day from standard foods and from 
food labels.  
 Treating hypoglycaemia.  
 Homework: recording carbohydrate intake, insulin doses and blood 
glucose levels for a week. 
Day two 
 Calculation of personal insulin:CP ratios 
 How to correct high blood glucose levels with an insulin correction 
dose 
 Insulin adjustment for snacks, illness, exercise and alcohol. 
 Practical: calculating mealtime carbohydrate loads and injecting 
matching insulin doses. 
 Practical: adjusting insulin:CP ratios and correction factors 
Individual review 
 
 Review method and participant  understanding 
 Troubleshooting 
Figure 2 MATCH IT programme content 
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3.4 Statistical analyses 
Data was analysed using the statistical package SPSS Statistics 19 (IBM). For all tests 
an α-level of 0.05 (two-tailed) was considered statistically significant and confidence 
intervals of 95% were used to interpret findings; exact significances were calculated 
because the sample size was small.  
Descriptive statistics were used to explore the data initially followed by the use of 
appropriate graphs and inferential statistics to highlight trends or differences. 
Preliminary analyses, namely Shapiro-Wilk tests, indicated that some variables 
followed the distribution of a normal Gaussian curve. The Shapiro-Wilk test is 
appropriate for 3>n<5000 (Royston, 1995), but, although it performs better than other 
tests for normality when using small sample sizes, it has low power to detect deviations 
from a normal distribution in a very small sample size such as n<10 (Razali & Wah, 
2011), as was the case in the present research. It was therefore interpreted in 
conjunction with histograms, Q-Q plots and detrended Q-Q plots.  
Visual inspection of the data was challenging due to the small sample size but showed 
skewed data and the presence of outliers in several variables, for example HbA1c, TDI, 
and BMI, despite normality tests signifying no significant difference from a normal 
distribution. Examples of such normality test results and histograms, Q-Q plots and 
detrended Q-Q plots are provided in Appendix 11. Log, square root and reciprocal 
transformations were unsuccessful at creating normally distributed data in those that 
were not normally distributed. Non-parametric tests were therefore used when 
comparing actual values, as these are robust to deviations from the normal distribution. 
Medians and interquartile ranges were calculated as these measures of central 
tendency and spread are less sensitive to the presence of outliers. Chi-squared was 
used to examine the number of participants allocated to each group. Fisher’s exact test 
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was used to investigate the relationship between group allocation and drop-out, 
number of females in each group, and physical activity, as an expected frequency of 
n<5 occurred in some groups.  
It was not possible to calculate percentage change in variables over time for all 
variables as QoL data included scores of zero from which it is not possible to calculate 
percentage change. Mann Whitney U tests were therefore used to explore actual 
change in biomedical and psychosocial variables from baseline to 6 months as a result 
of group allocation, and relationship of HbA1c to participant drop-out. Wilcoxon signed-
rank tests for related samples compared the distribution of medians of sequential 
baseline and six month biomedical and psychosocial variables within each group. In 
Group I only a Friedman ANOVA test was used to detect differences in sequential 
biomedical and psychosocial data from baseline, six and twelve months. Data was 
analysed per-protocol except for attrition rate.  
In Group D only 2 participants provided data at twelve months severely limiting 
statistical analysis. Discussion and analysis of the data was inappropriate as the 
sample may be misrepresentative of the participant group as a whole. Twelve month 
data for these two participants are therefore provided as means (median and 
interquartile range not possible) but excluded from analyses and graphs. 
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4.  Results 
4.1 Participant flow 
Seventy-nine potential participants were contacted regarding the MATCH IT study. Of 
the forty-one participants identified as eligible, nineteen were randomised representing 
a 46% uptake of the research project. Figure 3 illustrates participant flow through the 
study. Only nine participants provided data at all three time points resulting in a 53% 
attrition rate overall. By 12 months significantly more participants had left the study in 
the delayed intervention arm (8 out of 10 participants) than in the immediate 
intervention arm (2 out of 9 participants) (p=0.023). Of those participants from both 
groups that withdrew from the study, 4 (40%) dropped out during or after the MATCH 
IT course compared to 6 participants (60%) who dropped out prior to receiving any 
carbohydrate counting and flexible insulin dosing training. HbA1c at baseline did not 
differ between study completers and non-completers (n=19, U=36.5, p=0.497). Not all 
individuals who completed MATCH IT used the technique consistently but adherence 
to carbohydrate counting and insulin dose adjustment principles were not measured. 
4.2 Baseline characteristics 
Overall the group consisted of older, obese adults with poorly controlled T2DM (Error! 
Not a valid bookmark self-reference.). All participants were Caucasian and all took 
both basal and bolus insulin. 47% (8 participants) were on insulin glargine, 47% (8 
participants) were on insulin detemir and 6% (1 participant) used isophane insulin as a 
long-acting insulin. 88% (15 participants) used insulin aspart as a prandial insulin whilst 
6% (1 participant) used insulin glulisine and 6% (1 participant) used insulin lispro. No 
participant had ever experienced severe hypoglycaemia.  
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At baseline Group I and Group D were similar with no statistical differences in 
demographic or biomedical characteristics between the groups (Error! Not a valid 
bookmark self-reference.) or in quality of life (QOL), treatment satisfaction scores or 
perceived hyperglycaemia (Table 2). However participants in Group I perceived they 
had a significantly higher number of episodes of hypoglycaemia compared to Group D 
at baseline. 
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19 randomised at Visit 1 
 
 
7 attend Visit 2 
Weight, BMI, waist circumference data 
unavailable for 1 
 
 
7 attend Visit 3 
 
 
2 attend Visit 3 
 
79 potential 
participants 
contacted 
 
34 not eligible 
22 did not wish to participate 
4 did not respond & unable to 
contact 
 
 
10 attend Visit 2 
 
 
9 assigned to Group I 
 
 
10 assigned to Group D 
 
5 drop out after Visit 2 (4 due to 
health, 1 for personal reasons) 
3 drop out after MATCH IT (all lost to 
follow-up) 
 
1 drops out after Visit 1 due to illness 
1 drops out after MATCH IT for 
personal reasons 
Figure 3 Consort flowchart indicating participant flow through study 
35 
 
Table 1 Comparison of baseline demographic and biomedical 
characteristics between groups. Values are median (interquartile range) 
unless otherwise stated.  
 
Variable 
Group I 
n=7 
Group D 
n=10 
Statistical values 
Number of patients 
(% in parentheses) 
7 (41) 10 (59) χ²(1)=0.529 p=0.629 
Number of females (% 
in parentheses) 
3 (43) 3 (30) p=0.644 
Age (years)  66 (55-69) 61 (53-70) U=31.0 p=0.740 
Duration of diabetes 
(years) 
17.0 (15.0-28.0) 11.0 (7.5-28.5) U=18.5 p=0.109 
HbA1c (mmol/mol) 58 (45-66) 74 (47-81) U=48.5 p=0.193 
Total daily insulin 
dose (units) 
84 (42-116) 71 (48-143) U=33.0 p=0.887 
Episodes of 
hypoglycaemia per 
month 
1.0 (1.0-3.0) 0.5 (0.0-4.7) U=25.0 p=0.364 
Weight (kg) 
93.6  
(85.5-105.0) 
99.9  
(93.4-111.1) 
U=47.0 p=0.270 
BMI (kg/m²) 31.6 (27.1-34.3) 33.3 (31.9-35.5) U=46.0 p=0.315 
Waist circumference 
(cm) 
118.0  
(111.0-121.0) 
118.5  
(113.3-127.0) 
U=37.5 p=0.813 
Systolic blood 
pressure (mmHg) 
133 (100-156) 133 (123-152) U=35.5 p=1.000 
Diastolic blood 
pressure (mmHg) 
70 (60-79) 76 (67-87) U=44.5 p=0.364 
Total cholesterol 
(mmol/l) 
3.0 (2.7-4.0) 3.9 (3.6-4.6) U=51.5 p=0.109 
HDL cholesterol 
(mmol/l) 
1.0 (0.8-1.2) 1.1 (0.8-1.2) U=34.0 p=0.962 
Triglycerides (mmol/l) 1.4 (1.2-2.8) 2.3 (1.3-2.9) U=38.5 p=0.740 
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Table 2 Comparison of baseline QoL and treatment satisfaction scores 
between groups. Values are median (interquartile range). 
 
Variable 
Group I 
n=7 
Group D 
n=10  
Statistical values 
Present quality of 
life ¤
 1.0 (0-1.0) 1.0 (0-2.0) U=40.5 p=0.601 
Impact of diabetes 
on quality of life ¥ 
-2.0 (-2.0 -  -1.0) -2.0 (-2.3 - -1.0) U=36.0 p=1.000 
Average weighted 
impact of diabetes 
on quality of life  
-2.8 (-4.5 - -0.8) -3.7 (-4.3 – 0) U=38.0 p=0.813 
Weighted impact of 
diabetes on 
“freedom to eat as I 
wish”  
-4.0 (-6.0 - -1.0) -4.0 (-7.5 – 0) U=33.0 p=0.918 
Weighted impact of 
diabetes on 
“freedom to drink as 
I wish”  
-2.0 (-4.0 – 0) -4.0 (-6.0 – 0) U=27.5 p=0.681 
Overall treatment 
satisfaction  
28.0 (22.0-36.0) 25.0 (23.0-29.0) U=22.5 p=0.536 
Perceived 
hyperglycaemia  
2.0 (2.0-5.0) 2.0 (0-4.0) U=19.5 p=0.336 
Perceived 
hypoglycaemia  
3.0 (2.0-4.0) 1.0 (0.3-1.8) U=8.0 p=0.021*** 
General well-being 19.0 (14.0-31.0) 25.0 (12.8-27.5) U=34.0 p=0.962 
*** denotes statistically significant result at α-level of 0.05 
¤ scored from -3 (extremely bad) to +3 (excellent) 
¥ scored from -3 (maximum negative impact) to +3 (maximum positive impact) 
 scored from -9 (maximum negative impact) to +9 (maximum positive impact) 
 scored from 0 to 36, the higher the score, the higher the treatment satisfaction 
 scored from 0 to 6, the higher the score, the greater the perceived frequency 
 scored from 0 to 36, the higher the score, the higher the well-being 
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4.3 Primary outcomes 
Table 3 shows the change in the primary outcomes HbA1c and QoL scores at 6 and 12 
months. In Group I at 6 months QoL, as measured by the average weighted impact 
(AWI) of diabetes on QoL, was significantly improved. Results suggest the 
improvement may have been sustained through to 12 months but 12 month data failed 
to reach statistical significance. At 6 and 12 months there were no significant 
differences within or between Group I and Group D in HbA1c and other measures of 
QoL. Primary outcome results are described in more detail in the following sections. 
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Table 3 Primary outcomes baseline through 12 months: differences within and between Group I and Group D.              
Values are median (interquartile range) unless otherwise stated. 
Variable Group Baseline 6 months 12 months 
Difference 
within groups 
baseline to 6 
months 
Difference 
within groups 
baseline 
through 12 
months 
Difference 
between 
groups at 6 
months 
HbA1c (mmol/mol) 
Group I 
n=7 
58 
(45-66) 
53 
(40-66) 
58 
(39-67) 
z=-0.679 
p=0.563 
χ²(2)=0.963 
p=0.680 
U=52.0 
p=0.109 
Group D 
n=10 
74 
(47-81) 
69 
(49-76) 
71 ȹ 
z=-1.585 
p=0.121 
- 
Present quality of 
life ¤ 
Group I 
n=7 
1.0 
(0-1.0) 
1.0 
(0-2.0) 
1.0 
(1.0-2.0) 
z=-0.816 
p=0.750 
χ²(2)=1.50 
p=0.815 
U=35.0 
p=1.00 
Group D 
n=10 
1.0 
(0-2.0) 
1.0 
(0.8-2.0) 
1.5 ȹ 
z=-0.333 
p=1.000 
- 
Impact of diabetes 
on quality of life ¥ 
Group I 
n=7 
-2.0  
(-2.0 - -1.0) 
-2.0 
(-2.0 – 0) 
-1.0 
(-2.0 – 0) 
z=-1.342 
p=0.500 
χ²(2)=2.00 
p=0.556 
U=40.0  
p=0.669 
Group D 
n=10 
-2.0 
(-2.3 - -1.0) 
-1.0 
(-1.5 - -0.8) 
-1.5 ȹ 
z=-1.511 
p=0.250 
- 
¤ scored from -3 (extremely bad) to +3 (excellent) 
¥ scored from -3 (maximum negative impact) to +3 (maximum positive impact) 
ȹ 
n=2, mean value provided 
39 
 
Table 3 (Continued) 
 
 scored from -9 (maximum negative impact) to +9 (maximum positive impact) 
ȹ 
n=2, mean value provided 
*** denotes statistically significant result at α-level of 0.05 
Variable Group Baseline 6 months 12 months 
Difference 
within groups 
baseline to 6 
months 
Difference 
within groups 
baseline 
through 12 
months 
Difference 
between 
groups at 6 
months 
Average weighted 
impact of diabetes 
on quality of life  
Group I 
n=7 
-2.8 
(-4.5 - -0.8) 
-1.6 
(-2.9 - -0.4) 
-1.0 
(-1.7 - -0.6) 
z=-2.028 
p=0.047*** 
χ²(2)=6.00 
p=0.051 
U=39.0 
p=0.740 
Group D 
n=10 
-3.7 
(-4.3 – 0) 
-1.9 
(-3.9 - -0.1) 
-2.76 ȹ 
z=-1.244 
p=0.250 
- 
Weighted impact of 
diabetes on 
“freedom to eat as 
I wish”  
Group I 
n=7 
-4.0 
(-6.0 - -1.0) 
-2.0 
(-6.0 – 0) 
-2.0 
(-9.0 - -1.0) 
z=-1.890 
p=0.125 
χ²(2)=3.90 
p=0.177 
U=36.5 
p=0.887 
Group D 
n=10 
-4.0 
(-7.5 – 0) 
-3.0 
(-6.0 – 0) 
-1.0 ȹ 
z=-0.542 
p=0.688 
- 
Weighted impact of 
diabetes on 
“freedom to drink 
as I wish” 
Group I 
n=7 
-2.0 
(-4.0 – 0) 
-1.0 
(-2.0 – 0) 
-1.0 
(-9.0 - -1.0) 
z=-1.225 
p=0.313 
χ²(2)=5.00 
p=0.852 
U=29.0 
p=0.601 
Group D 
n=10 
-4.0 
(-6.0 – 0) 
-2.0 
(-4.0 – 0) 
0 ȹ 
z=-0.707 
p=0.750 
- 
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4.3.1 HbA1c 
HbA1c decreased non-significantly in both Group I and Group D between baseline and 
6 months, and in Group I increased back to baseline by 12 months (Figure 4).  
The number of participants achieving HbA1c <53mmol/mol in Group I and Group D 
was equal at baseline (29% and 30% respectively). By 6 months participants achieving 
HbA1c <53mmol/mol had increased to 57% in Group I whilst remaining constant at 
30% in Group D however there was not a significant association between group 
allocation and achievement of HbA1c <53mmol/mol at 6 months (p=0.350).  
 
 
 
 
 
 
 
 
Figure 4 Change in HbA1c baseline to 6 months 
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4.3.2 Quality of life 
Patient-reported present QoL did not change in either group at any time point; impact 
of diabetes on QoL improved non-significantly in both Group I and Group D (Figure 5). 
AWI of diabetes on QoL improved in both groups and was significantly improved in 
Group I at 6, but not 12 months (Figure 6) with a large effect size due to the 
intervention at 6 months (r=-0.54). Perceived dietary freedom improved non-
significantly in both groups (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Change in present QoL and impact of diabetes on QoL baseline to 6 months. 
Error bars depict the interquartile range. 
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Figure 6 Change in average weighted impact, “freedom to eat as I wish” and “freedom  
to drink as I wish” baseline to 6 months. Error bars depict the interquartile range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
*** denotes statistically significant result at α-level of 0.05 
 
*** 
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4.4 Secondary biomedical outcomes 
At 6 months TDI had decreased by a clinically relevant quantity in Group I but there 
were no significant differences between Group I and Group D for any secondary 
outcome (Table 4). There was a trend towards reduced waist circumference in both 
groups, and towards lower diastolic blood pressure in Group D, at 6 months. Total 
cholesterol increased by a clinically relevant, but non-significant amount at 6 months in 
Group I, this was accompanied by a small non-significant rise in HDL cholesterol. 
Episodes of hypoglycaemia were low and no participant experienced severe 
hypoglycaemia.  
In addition the confounding factors alcohol intake and physical activity level did not vary 
significantly. There was no difference in self-reported alcohol intakes between groups 
at baseline (U=40.5 p=0.601) or 6 months (U=40.0 p=0.669), and no significant change 
within Group I at 6 months (z=-0.37, p=0.875) or 12 months (χ²(2)=2.80, p=0.278), nor 
within Group D at 6 months (z=-1.35, p=0.219). Alcohol intakes were low on the whole, 
but variable, with baseline levels (median and interquartile range) in Group I at 0 
units/week (0-4.5) and in Group D at 1.4 units/week (0-13.6). There was also no 
difference in self-reported levels of physical activity between groups at baseline 
(p=1.000) or 6 months (p=1.000), and no significant change within Group I at 6 months 
(z=0, p=1.000) or 12 months (χ²(2)=0, p=1.000), nor within Group D at 6 months (z=-
1.73, p=0.250). At baseline 29% of all participants classed themselves as sedentary, 
47% as lightly active and 24% as moderately active. 
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Table 4 Secondary biomedical outcomes at baseline through 12 months:  
differences within and between Group I and Group D. Values are median (interquartile range) unless otherwise stated. 
ȹ 
n=2, mean value provided 
Variable Group Baseline 6 months 12 months 
Difference 
within groups 
baseline to 6 
months 
Difference 
within groups 
baseline 
through 12 
months 
Difference 
between 
groups at 6 
months 
Total daily 
insulin dose 
(units) 
 
Group I 
n=7 
84 
(42-116) 
52 
(36-84) 
74 
(33-160) 
z=-0.676 
p=0.578 
χ²(2)=1.556 
p=0.502 U=38.0 
p=0.813 
Group D 
n=10 
71 
(48-143) 
73 
(43-145) 
105 ȹ 
z=-0.631 
p=0.625 
- 
Episodes of 
hypoglycaemia 
per month 
Group I 
n=7 
1.0 
(1.0-3.0) 
1.5 
(0.5-3.5) 
1.5 
(0.0-3.5) 
z=0 
p=1.000 
χ²(2)=0.000 
p=1.000 U=26.5 
p=0.417 Group D 
n=10 
0.5 
(0.0-4.7) 
0.4 
(0.0-4.3) 
0.5 ȹ 
z=-0.135 
p=1.000 
- 
BMI (kg/m²) 
Group I 
n=6 
31.6 
(27.1-34.3) 
29.7 
(27.4-35.4) 
30.1 
(27.0-34.4) 
z=-0.105 
p=1.000 
χ²(2)=0.333 
p=0.956 U=40.0 
p=0.313 Group D 
n=10 
33.3 
(31.9-35.5) 
33.9 
(30.9-35.0) 
33.1 ȹ 
z=-0.357 
p=0.770 
- 
Waist 
circumference 
(cm) 
Group I 
n=6 
118.0 
(111.0-121.0) 
113.5 
(99.4-118.3) 
108.5 
(102.5-120.5) 
z=-1.992 
p=0.063 
χ²(2)=4.261 
p=0.136 
U=43.5 
p=0.147 Group D 
n=10 
118.5 
(113.3-127.0) 
119.8 
(109.9-122.1) 
121.0 ȹ 
z=-1.785 
p=0.078 
- 
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Table 4 (Continued) 
ȹ 
n=2, mean value provided 
Variable Group Baseline 6 months 12 months 
Difference 
within groups 
baseline to 6 
months 
Difference 
within groups 
baseline 
through 12 
months 
Difference 
between 
groups at 6 
months 
Systolic blood 
pressure 
(mmHg) 
Group I 133 (100-156) 136 (135-150) 131 (117-143) 
z=-0.676 
p=0.578 
χ²(2)=0.286 
p=0.964 U=21.0 
p=0.193 
Group D 133 (123-152) 124 (113-143) 125 ȹ 
z=-1.636 
p=0.113 
- 
Diastolic blood 
pressure 
(mmHg) 
Group I 70 (60-79) 72 (57-76) 73 (70-76) 
z=0.530 
p=0.719 
χ²(2)=2.296 
p=0.358 U=29.5 
p=0.601 
Group D 76 (67-87) 68 (63-74) 61 ȹ 
z=-1.788 
p=0.082 
- 
Total cholesterol 
(mmol/l) 
 
Group I 3.0 (2.7-4.0) 3.5 (2.5-4.0) 3.7 (2.7-4.8) 
z=-0.315 
p=0.781 
χ²(2)=2.846 
p=0.258 U=52.5 
p=0.088 
Group D 3.9 (3.6-4.6) 4.0 (3.6-5.0) 4.0  ȹ 
z=-0.672 
p=0.523 
- 
HDL cholesterol 
(mmol/l) 
Group I 1.0 (0.8-1.2) 1.1 (0.9-1.2) 1.1 (0.9-1.2) 
z=-0.138 
p=1.000 
χ²(2)=0.250 
p=0.928 U=30.5 
p=0.669 
Group D 1.1 (0.8-1.2) 0.9 (0.8-1.2) 0.9 ȹ 
z=-1.633 
p=0.188 
- 
Triglycerides 
(mmol/l) 
Group I 1.4 (1.2-2.8) 1.6 (0.8-2.5) 1.1 (0.8-2.7) 
z=-0.841 
p=0.469 
χ²(2)=1.280 
p=0.558 U=43.0 
p=0.475 
Group D 2.3 (1.3-2.9) 2.1 (1.3-3.3) 2.7 ȹ 
z=0 
p=1.000 
- 
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4.5 Secondary psychosocial outcomes 
Changes in secondary psychosocial outcomes at 6 and 12 months are shown in Table 
5. At 6 months there were no significant differences in the secondary psychosocial 
outcomes between Group I and Group D. There was a trend towards a reduction in 
perceived frequency of hypoglycaemia in Group I at 6 months and by 12 months this 
had reached statistical significance. Conversely there was a trend towards increased 
perceived frequency of hypoglycaemia in Group D at 6 months. There was also a trend 
towards improved general well-being in Group I at 6 months, this improvement 
increased further at 12 months but was not significant.  
Participants in Group I were much more satisfied with their diabetes management 
following carbohydrate counting and insulin dose adjustment training (Figure 7). They 
also felt they experienced less hyperglycaemia, but scores indicated no perceived 
change in frequency of hypoglycaemia (median -1.0 and 0, interquartile range -1.0 – 
1.0 and -1.0 – 1.0 respectively; scored from -3 [much less now] to +3 [much more 
now]). 
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Table 5 Secondary psychosocial outcomes at baseline through 12 months:  
differences within and between Group I and Group D.  Values are median (interquartile range) unless otherwise stated. 
 
Variable Group Baseline 6 months 12 months 
Difference 
within groups 
baseline to 6 
months 
Difference 
within groups 
baseline 
through 12 
months 
Difference 
between 
groups at 6 
months 
Treatment 
satisfaction 
Group I 
28.0 
(22.0-36.0) 
31.0 
(28.0-35.0) 
30.0  
30.0-35.0) 
z=-1.572 
p=0.156 
χ²(2)=1.000 
p=0.653 U=24.5 
p=0.315 
Group D 
25.0 
 (23.0-29.0) 
29.0 
(24.0-34.0) 
27.5 ȹ 
z=-1.620 
p=0.188 
- 
Perceived 
hyper- 
glycaemia  
Group I 
2.0 
(2.0-5.0) 
2.0 
 (2.0-4.0) 
2.0 
 (2.0-4.0) 
z=-0.828 
p=0.563 
χ²(2)=2.375 
p=0.457 U=29.5 
p=0.601 
Group D 
2.0 
(0-4.0) 
2.0 
(1.8-3.3) 
2.0 ȹ 
z=-0.343 
p=0.844 
- 
Perceived hypo-
glycaemia  
Group I 
3.0 
(2.0-4.0) 
2.0 
(0-2.0) 
1.0 
(1.0-2.0) 
z=-2.060 
p=0.063 
χ²(2)=8.435 
p=0.008*** U=46.5 
p=0.114 
Group D 
1.0 
(0.3-1.8) 
3.0 
(1.0-4.0) 
1.5 ȹ 
z=-1.597 
p=0.094 
- 
General well-
being  
Group I 
19.0 
(14.0-31.0) 
22.0 
(18.0-32.0) 
24.0 
(18.0-33.0) 
z=-1.992         
p=0.063 
χ²(2)=1.000 
p=0.640 U=33.0 
p=0.887 
Group D 
25.0 
(12.8-27.5) 
25.0 
(18.0-29.3) 
27.0 ȹ 
z=-1.672 
p=0.109 
- 
*** denotes statistically significant result at α-level of 0.05 
 scored from 0 to 36, the higher the score, the higher the treatment satisfaction 
 scored from 0 to 6, the higher the score, the greater the perceived frequency 
 scored from 0 to 36, the higher the score, the higher the well-being 
ȹ 
n=2, mean value provided 
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ǂ scored from -3 (much less now) to +3 (much more now) 
 Figure 7 Diabetes Treatment Satisfaction Questionnaire (change): 
treatment satisfaction results for Group I at 6 months.                            
Error bars depict interquartile range. 
 
 
 
 
ǂ 
ǂ 
ǂ 
ǂ 
ǂ 
ǂ 
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5.  Discussion 
5.1 Summary of main results 
This research indicates that carbohydrate counting and flexible insulin dosing is 
feasible in adults with T2DM on basal-bolus insulin. MATCH IT education, compared 
with standard care, resulted in a statistically significant improvement in quality of life at 
6 months enabling rejection of the null hypothesis that QoL is not affected by 
carbohydrate counting and flexible insulin dosing. It was also associated with a 
significant reduction in perceived frequency of hypoglycaemia at 12 months and there 
was a trend towards improved general psychological well-being whilst individuals 
continuing to receive standard care reported a trend towards greater perceived 
hypoglycaemia.  
HbA1c decreased non-significantly in both the immediate and delayed intervention 
group at 6 months, without a notable increase in actual episodes of hypoglycaemia. It 
was not possible to reject the null hypothesis that HbA1c is unaffected by carbohydrate 
counting and flexible insulin dosing. Participants in Group I had lower total daily insulin 
doses (TDI) at 6 months compared with baseline, but this was a non-significant 
decrease, whereas participants in Group D had no marked change in TDI. There was 
no significant increase in BMI and waist circumference in Group I despite increased 
dietary freedom however there was a clinically relevant but non-significant increase in 
total cholesterol in Group I.  
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5.2 Participants 
The number of participants recruited into the study was within the projected range 
Implications of the uptake and drop-out rates are considered here with respect to 
clinical practice.  
The MATCH IT drop-out rate was high at 53% and only nine participants provided data 
at all three time-points. A significantly greater proportion of the participants that left the 
study early dropped out of Group D, the delayed intervention group, compared to 
Group I, the immediate intervention group. Due to the small sample size, it is possible 
this occurred by chance. The demographic profile of the participants revealed they 
were generally older adults with diabetes complications and other pre-existing medical 
conditions which resulted in poor health preventing continuation in the research for 
some participants.  
Alternatively a greater attrition rate in the delayed start arm of the study could indicate 
that providing a timely response is important to engage this population in diabetes 
education. One model of health behaviour proposed by Prochaska and DiClemente 
(1982) identifies several stages of readiness to change that flow cyclically. Participants 
may have consented to contribute to the study when they were motivated to improve 
their diabetes control and a 6 month wait to commence the education resulted in, or 
coincided with, a change in their motivation levels. 
Of the participants that dropped out of the study, 40% dropped out of the study post 
education suggesting that improved knowledge may not be a significant factor in 
increasing readiness to change. However the larger proportion (60%) dropped out 
before commencing the educational intervention signifying the intervention was not 
likely to be the cause for study withdrawal. This may suggest a contrast to other 
evidence in T2DM which demonstrated higher drop-out rates in the carbohydrate 
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counting and insulin dose adjustment arms of the study (Bergenstal et al., 2008). This 
highlights the intensive nature of this diabetes management method, plus the numerical 
and analytical skills required, and therefore its unsuitability for some individuals. Often 
more complex medication regimes result in poorer adherence to treatment (Donnan, 
MacDonald, & Morris, 2002). Nevertheless in the present study this may not have been 
as much of a barrier to study completion as in other research populations. This could 
be explained by MATCH IT participants being drawn from the relatively affluent 
Cheshire area, which may denote higher educational attainment and less social 
deprivation (Western Cheshire Primary Care Trust, 2007) and the involvement of self-
selected motivated individuals, although the latter is the case with any research.  
In clinical practice, it could be expected that a proportion of adults with T2DM would 
decline this management method, or be deemed unsuitable, due to intensity of 
personal input. However just under half of the individuals invited to take part in this 
research project accepted, suggesting that many adults with T2DM currently on 
standard basal-bolus insulin regimes would consider learning how to adjust their own 
insulin. MATCH IT uptake may also not represent uptake in a real clinical setting as 
some individuals preferred not to participate in the project due to its experimental 
nature, rather than the diabetes management method proposed.  
In summary patients should be carefully selected for carbohydrate counting and flexible 
insulin dosing education as levels of commitment and motivation are required to be 
high to successfully utilise this method, and inappropriate patient selection could result 
in wasted resources if individuals are unable or unwilling to employ the technique. 
Furthermore these results suggests that waiting lists for interventions such as 
carbohydrate counting and insulin dose adjustment training should be kept short, to at 
least less than 6 months, and if possible self-referrals be utilised, to ensure 
engagement with participants at an appropriate time in their motivation levels.  
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5.3 Primary outcome: HbA1c 
5.3.1 HbA1c results 
Glycaemic control, as represented by HbA1c, improved in both in Group I and Group D 
at 6 months; these changes were not statistically significant. Achieving a reduction in 
HbA1c is more challenging when glycaemic control is already close to optimal as the 
risk of hypoglycaemia is increased and there is less potential to affect glucose 
excursions from normoglycaemia. Therefore the reduction from a median HbA1c of 
58mmol/mol to 53mmol/mol in Group I is more notable than the reduction from 
74mmol/mol to 69mmol/mol in Group D at 6 months. This is reflected in the reduced 
perception of hyperglycaemia compared to past diabetes management in Group I at 6 
months, and also in the greater increase in individuals achieving a HbA1c 
<53mmol/mol in Group I compared to Group D, however the latter should be 
interpreted in light of some Group I participants’ pre-existing proximity to this target. 
5.3.2  Interpretation of HbA1c results 
The reason HbA1c improved in both the control and intervention group is unclear. 
Participants were excluded if anti-diabetic medication was altered during the study; this 
did not occur and therefore pharmacological agents cannot account for this difference. 
Other confounding factors, BMI, self-reported physical activity level and alcohol intake, 
also did not significantly alter but some determinants of glycaemic control not 
measured, such as dietary composition and glycaemic index of carbohydrates, may 
have contributed to the these results. It is possible that study participation alone may 
have resulted in improved glycaemic control in either, or both, arms due to increased 
consciousness of health decisions and improved support and motivation provided by 
an increased frequency of appointments with a healthcare professional. Furthermore 
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as individuals in Group D were aware of the nature of the study, they may have 
deliberately or unconsciously standardised their carbohydrate intake. 
Another element introducing variability in response to MATCH IT may have been in 
disparities in the use of this management technique. A reduction in HbA1c in T1DM as 
a result of carbohydrate counting training derives from a number of behaviours, not just 
matching insulin to carbohydrate load but also prompt and appropriate treatment of 
hypoglycaemia, correct timing of insulin doses and adjusting insulin for exercise and 
alcohol. The difference in the frequency of display of these behaviours has been 
associated with up to a 10mmol/mol difference in HbA1c in adults with T1DM who 
adjust their insulin (Delahanty & Halford,1993).  
The DAFNE Study Group (2002), in the same study design as the current research, 
found that HbA1c decreased from 79mmol/mol to 68mmol/mol in adults with T1DM 
who were trained in carbohydrate counting and insulin dose adjustment. This reduction 
of 11mmol/mol in HbA1c is greater than the 5mmol/mol reduction observed in both 
Group I and Group D in the present study. However a decrement of 5mmol/mol 
remains a notable clinical outcome and is associated with a 15-20% risk reduction for 
diabetes-related complications (UKPDS Group, 1998). Moreover HbA1c does not 
provide detail about glucose variability; it may be proposed that MATCH IT has the 
potential to improve glucose excursions in the post-prandial period more than other 
insulin regimes. As post-prandial glucose excursions are more closely associated with 
CVD risk than fasting glycaemia (Horton, 2009), MATCH IT may have an enhanced 
capability in diabetes-related macrovascular disease prevention. 
5.3.3 Physiology of mechanisms of impact  
No conclusive evidence demonstrates the impact of carbohydrate counting and insulin 
dose adjustment on glycaemic control; whether this study failed to demonstrate a 
significant effect due to a genuine lack of association or on methodological grounds 
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cannot be surmised. Carbohydrate counting and insulin dose adjustment could have a 
different outcome in T2DM compared to T1DM for several reasons. Firstly HbA1c may 
not have as much potential to decrease for adults with T2DM who carbohydrate count 
compared to those with T1DM who do so.  Some individuals with T2DM are capable of 
a greater degree of physiological regulation of blood glucose levels as a result of 
residual endogenous insulin production thereby limiting the impact of flexible insulin 
dosing. For others with little remaining pancreatic β-cell function, the effect on 
glycaemic control may be conjectured to be similar to T1DM. Alternatively this diabetes 
management method could have a greater impact on glycaemic control in T2DM, with 
less accuracy in carbohydrate counting necessary to achieve this, as endogenous 
insulin may assist in attenuation of glycaemic variability.  
Moreover interpretation of MATCH IT results is complicated by emerging evidence that 
some prandial insulins have a reduced hypoglycaemic effect and delayed action in 
obese individuals with T2DM due to decreased adipose tissue blood flow and larger 
insulin doses (Gagnon-Auger et al., 2010). This provides an additional possible 
mechanism for limited efficacy in reducing post-prandial hyperglycaemia compared to 
T1DM, irrespective of carbohydrate load matching. It is also possible that the 
pharmacokinetics and pharmacodynamics of prandial analogue insulin aspart, lispro 
and glulisine, used by participants in this study, are affected differently in response to 
both obesity and T2DM (Barnett, 2006). Unfortunately the present study is unable to 
elucidate the complex relationship between the effect of carbohydrate counting and 
insulin dose adjustment, endogenous insulin production, obesity and choice of prandial 
insulin. Adults with T2DM represent a diverse group which could result in a 
heterogeneous response to flexible insulin dosing and it is possible only a subset of 
individuals with T2DM would benefit from this management approach.  
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5.3.4 Comparison with existing literature 
Comparison with the DAFNE study is limited by the different participant population, and 
as a less intensive education programme was used in MATCH IT (5 full days versus 2 
half-days respectively).  Additionally the types of insulin used by participants in the 
DAFNE trial are not disclosed; older isophane long-acting insulin and soluble prandial 
insulin, with different activity profiles than newer analogue long-acting and prandial 
insulins, were likely utilised to a greater degree than in the present study. Prandial 
analogue insulin lispro and insulin aspart are both associated with lower post-prandial 
blood glucose levels and lower HbA1c than soluble insulins (Anderson et al., 1997; 
Raskin, Guthrie, Leiter, Riis, & Jovanovic,, 2000) which means the 11mmol/mol HbA1c 
reduction accounted for by flexible insulin dosing in the DAFNE study, and the 
5mmol/mol reduction in the present study discussed earlier should be compared with 
caution. 
The results of this study for improved glycaemic control are consistent with results from 
existing literature on carbohydrate counting and flexible insulin dosing in T2DM 
however cannot be definitively attributed to this technique due to improved glycaemic 
control in the control group. Compared to the present study, Bergenstal et al. (2008) 
found no difference in the drop in HbA1c resulting from training adults in carbohydrate 
counting, or use of a simple titration algorithm, at 17mmol/mol and 16mmol/mol 
respectively. Results are not directly comparable as Bergenstal et al. (2008) initiated 
basal-bolus insulin in some participants whereas this research included only individuals 
already using a basal-bolus insulin regime for at least six months. Transfer from an 
ineffective insulin regime to a basal-bolus regime, together with a titration schedule, will 
undoubtedly cause a drop in HbA1c independent of carbohydrate counting and flexible 
insulin dosing, thereby accounting for the discrepancy between observed results in the 
two studies as glycaemic improvement is only partly attributable to carbohydrate 
counting and insulin dose adjustment training in Bergenstal et al.’s study (2008).  
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Additionally the cohort of participants in Bergenstal et al.’s study (2008) had a mean 
age of 55 years, a notable difference from the median age of 66 and 61 years in the 
intervention and control group of this study respectively. Younger adults can have very 
variable diets (Huang, Song, Schemmel & Hoerr, 1994) therefore commencing flexible 
insulin dosing in a slightly younger group of individuals could have a greater degree of 
impact upon glycaemic control than in an older group with more established eating 
patterns. 
5.3.5 Significance of results 
Overall optimal glycaemic control was not achieved by adults with T2DM who were 
carbohydrate counting and insulin dose adjusting in this study. Only 57% of participants 
achieved a HbA1c <53mmol/mol, arguably an appropriate individualised target for this 
population (Inzucchi et al., 2012). As research participants may be assumed to be a 
more motivated patient group it is disheartening that despite maximal diabetes 
pharmacological treatment and insulin adjustment only a small number achieved the 
recommended target. This is a widespread issue; nearly three-quarters of all adults 
with T2DM, and nearly two-thirds of adults with T2DM on insulin, fail to achieve a 
glycaemic target of <48mmol/mol (Health and Social Care Information Centre, 2012; 
Holman et al. 2009). Although it is acknowledged this target is likely inappropriate for 
some, this demonstrates the challenges of attaining desirable blood glucose levels for 
all.  
In short, for some individuals with T2DM carbohydrate counting and flexible insulin 
dosing may have a glycaemic advantage over a standard insulin regime but this 
remains only an enhancement to an imperfect therapy. It is clear that more advanced 
treatment options to assist these individuals achieve near-normal glycaemia are 
required; research continues into promising alternatives and additions to current 
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treatment such as GLP-1 analogues, bolus insulin advisor meters and closed loop 
insulin pumps. .  
5.4 Primary outcome: Quality of life 
Compared to standard care, carbohydrate counting and insulin dose adjustment 
training resulted in a statistically significant improvement in QoL at 6 months, and a 
trend towards improved general well-being. Although not a primary outcome, the 
significance of general well-being, representing not just health-related quality of life, is 
also discussed within this section.  
On the whole, both the intervention and control group had improved median scores in 
the separate measures of QoL, which may have arisen by chance due to the small 
sample size, or have occurred simply as result of participating in the research and a 
greater sense of engagement with their health status, or improved knowledge without 
change in behaviour. As in other studies QoL improvements may not reach a level of 
significance until 12 months or beyond (DAFNE Study Group, 2002) suggesting a 
longer monitoring period may be necessary to fully appreciate changes in QoL. 
Baseline QoL scores were similarly low in the MATCH IT and DAFNE studies (DAFNE 
Study Group, 2002), and are consistent with other similar research (Mujika-Zabaleta, 
Forbes, While, Mold & Canga, 2010) . As individuals with the lowest QoL gain the most 
from carbohydrate counting and insulin dose adjustment (Byrne et al., in press), it could 
be proposed that MATCH IT would have a comparably positive impact to the DAFNE 
study. The following discussion will demonstrate that this was not exactly the case. 
The average weighted impact (AWI) on diabetes score that showed a significant 
change in Group I at 6 months represents the accumulated score of nineteen different 
QoL domains including freedom to eat and drink. The domain “Freedom to eat as I 
wish” showed improvement from baseline through to 12 months in both groups but a 
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greater improvement was seen in Group I. However as it did not change significantly, 
but the AWI score did, in conjunction with the trend towards improved general well-
being, this suggests greater improvements in QoL are occurring in areas other than 
dietary liberality. Interestingly dietary freedom is usually found to be the aspect of QoL 
most negatively impacted by diabetes (Bradley et al., 1999) and was therefore the 
aspect that improved most dramatically following DAFNE training (DAFNE Study 
Group, 2002). This is in contrast to MATCH IT results, perhaps because individuals 
with T2DM do not suffer the consequences of dietary lapses or misjudgements, the 
hyper- or hypoglycaemia, to the same degree that adults with T1DM do. Therefore 
despite carbohydrate counting and flexible insulin dosing appearing to relate 
predominantly to dietary freedom, in this study it clearly had a far-reaching positive 
impact on individuals’ lives. Emerging evidence may also provide an additional possible 
mechanism for improved QoL independent of dietary freedom. In a small pilot study, 
Penckofer et al. (2012) demonstrated a reduced QoL and negative moods in the 
presence of greater glycaemic variability. Although glucose excursions were not 
measured explicitly, MATCH IT data suggests attenuation of glycaemic variability 
through improvement or maintenance of HbA1c without increased incidence of 
hypoglycaemia. 
Finally it is important to highlight that MATCH IT did not to have a negative effect on 
participants’ QoL despite the increased focus on their medical condition, 
encouragement to perform home blood glucose monitoring more frequently, more daily 
insulin injections and the impact of scrutinising their dietary intake. It has been 
demonstrated that treatment intensity may decrease QoL (Wexlar et al., 2006) 
therefore elements of this management method must be negating this effect in both 
T1DM and T2DM. 
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Increased self-efficacy, the confidence in personal ability, is highly likely to be the factor 
underlying the observed association of increased patient input into personal health 
without deterioration of QoL and general well-being seen in the MATCH IT study. Low 
self-efficacy is related to low levels of diabetes-related QoL and poorer self-
management (Glasgow, Toobert, & Gillette, 2001). Likewise high self-efficacy is 
associated with greater adherence to health recommendations and better self-
management (Aljasem, Peyrot, Wissow & Rubin, 2001). Self-efficacy is the key to a 
positive feedback system that perpetuates enhanced self-management and QoL 
thereby improving glycaemic control and reducing risk of diabetes-related 
complications. Bradley and Gamsu (1994) further emphasise the close link between 
day-to-day QoL and blood glucose regulation as improving psychological well-being 
reduces stress hormone production resulting in more manageable blood glucose levels 
and, cyclically, improving glycaemic control enhances QoL by causing less anxiety 
regarding home blood glucose monitoring readings. Additionally diabetes knowledge 
and self-care behaviour are generally poorly correlated (Knight, Dornan, & Bundy, 
2006). MATCH IT, and similar interventions such as DAFNE, may be successful 
because they combine educational approaches with knowledge and behaviour 
components. They provide the reason for behaviour changes, such as knowledge 
about macronutrient effects on glycaemia, and provide the training and support to 
implement behaviours to utilise the new knowledge thereby substantially increasing 
users’ self-efficacy and resulting in both improved biomedical outcomes as well as 
patient-reported outcomes. 
It is now widely accepted that improved medical outcomes are not the only goal of 
healthcare interventions. The UK Government are committed to empowering people 
with chronic diseases (including diabetes) to take an active role in their own health care 
(Department of Health, 2010). Courses to enable chronic disease self-management are 
commonplace and are associated with improved self-efficacy, fatigue, anxiety, 
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depressed moods and health distress (Barlow, Wright, Turner & Bancroft, 2005) which 
contribute to overall quality of life. Similarly the National Service Framework for 
Diabetes (Department of Health, 2001), promotes fostering patients’ self-efficacy to 
optimally manage diabetes. The present study is in line with these current national 
recommendations.  
Again definitive conclusions about overall impact of carbohydrate counting and insulin 
dose adjustment training on QoL cannot be drawn from the present small study but 
individuals with T2DM already experience lower QoL than their peers (Holmes et al., 
2000) therefore any management methods that mitigate this reduction in QoL, as 
MATCH IT appears to, whilst not associated with a deterioration in glycaemic control, 
are of considerable value. 
5.5 Secondary outcomes 
5.5.1 Hypoglycaemia 
There was a trend towards a reduction in perceived frequency of unacceptably low 
blood glucose levels, measured by the DTSQ, at 6 months in Group I, and by 12 
months this had reached statistical significance. However this data is contradicted by 
the DTSQc results in Group I at 6 months which signify participants discerned no 
difference in incidence of hypoglycaemia when comparing their current and past 
diabetes management. Actual frequency of hypoglycaemic episodes was very low in 
both groups at all time-points, and comparable with other studies (Holman et al., 2007). 
No participants experienced severe hypoglycaemia either before or during the study. 
The number of reported hypoglycaemic episodes interestingly increased slightly in 
Group I at 6 months, although this was neither clinically relevant nor statistically 
significant and therefore could have occurred by chance. Likewise an increase in mild 
hypoglycaemia occurred in the carbohydrate counting arm of Bergenstal et al.’s study 
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(2008). Other possible reasons for the divergence in perceived and actual 
hypoglycaemia are discussed below.  
At baseline perceived frequency of unacceptably low blood glucose levels were 
significantly different in the two groups, with Group I feeling they experienced greater 
frequency of hypoglycaemic episodes than Group D. This could represent a greater 
anxiousness about hypoglycaemia in Group I which caused there to be an over-
representation of perceived hypoglycaemia incidence in the treatment satisfaction 
questionnaire, which when quantified, did not correspond to a greater self-reported 
frequency of hypoglycaemia. Alternatively the method of identifying frequency of 
hypoglycaemic episodes was limited to self-reporting which may not have been 
sensitive enough to show a genuinely greater number of hypoglycaemic episodes 
occurring in Group I. The reliability of retrospective recollection of hypoglycaemic 
episodes has not been explored in type 2 diabetes but literature in T1DM suggests 
collection of information about frequency of mild hypoglycaemic episodes over a week 
after their occurrence can be prone to significant recall bias (Pedersen-Bjergaard, 
Pramming & Thorsteinsson, 2003). This may also explain the contradictory results 
regarding perceived frequency of hypoglycaemia in the DTSQ and DTSQc; the DTSQ 
data is likely to be more robust. Therefore a more rigorous method of ascertaining 
blood glucose levels, for example periods of intensive monitoring accompanied by 
collection and analysis of all blood glucose values, could be used in a larger scale 
study and clarify the relationship between perceived and actual hypoglycaemia.  
A further explanation for the discrepancy could be the interpretation of the question in 
the DTSQ questionnaire “How often have your blood sugars been unacceptably low?” 
It is possible that the reassurance of the ubiquitousness of hypoglycaemia, attained 
from the interaction with group members, or the provision of information about 
glycaemic targets, has caused an alteration in what participants saw as an 
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unacceptably low blood glucose level at baseline compared to at 6 months. Moreover 
an increased sense of control over blood glucose levels could have decreased the 
perception of hypoglycaemia as it may have reduced a sense of helplessness 
surrounding hypoglycaemia if participants could attribute it to inappropriate insulin 
dosing for a carbohydrate load and/or activity.  
A reduction in perception of hypoglycaemia, even whilst incidence of hypoglycaemia 
does not change, is a beneficial outcome as it could represent improved coping with 
hypoglycaemia or increased understanding of the causes of hypoglycaemia which may 
leave the participant feeling better equipped to deal with, or prevent, hypoglycaemia. 
Hypoglycaemia and anxiety about hypoglycaemia in T2DM reduces QoL (de Grauw, 
Van de Lisdonk, Van Gerwen, Van den Hoogen & Van Weel, 2001; Irvine, Cox & 
Gonder-Frederick, 1992) plus has an impact on mortality and morbidity and can have 
substantial financial implications (Amiel, Dixon, Mann & Jameson, 2008). Risk of 
hypoglycaemia increases with intensification of treatment targets (Turner et al., 1998) 
therefore the lack of an increased rate of hypoglycaemia and reduced perception of 
hypoglycaemia in this study attests to the success of carbohydrate counting and 
flexible insulin dosing in providing a physiologically appropriate insulin dose. 
5.5.2 Total daily dose of insulin 
Total daily insulin dose (TDI) was decreased following MATCH IT education in Group I 
at 6 and 12 months, and increased in Group D at 6 months but no changes in this 
variable were significant. TDI is of interest as a proxy measure of appropriate insulin 
dosing; if TDI remains constant or decreases without significant deterioration of HbA1c, 
as occurred in Group I at both 6 and 12 months, it suggests that insulin provision has 
become optimised and dosing is occurring at physiologically appropriate times. This is 
subject to the confounding effects of changes in BMI, waist circumference and activity 
levels as insulin requirements vary in part due to body weight and insulin resistance 
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(De Fronzo, 2004). Activity levels did not significantly change in either group however 
BMI and waist circumference did decrease non-significantly in Group I. The reductions 
in TDI, BMI, waist circumference and HbA1c in Group I are inter-related; change in any 
one variable will likely influence the other two with causality being difficult to ascertain. 
An alternative explanation could be that better glycaemic management diminished 
glucose toxicity arising from hyperglycaemia in pancreatic β-cells, hence promoting 
insulin production and resulting in reduced exogenous insulin requirements (Leahy & 
Pratley, 2011). 
Many participants expressed a desire to lose weight during personal communication 
throughout the MATCH IT sessions. A reduction in TDI and flexible insulin dosing could 
produce unintentional weight loss through a reduction in the anabolic effect of insulin, 
reduction in hunger induced by subclinical over-insulinisation or a lower frequency of 
hypoglycaemia necessitating consumption of additional energy to correct blood glucose 
levels. Conversely flexible insulin dosing may have enabled participants to deliberately 
reduce their energy intake without concern about hypoglycaemia, or the motivation 
provided by health professional contact may have elicited dietary changes. The 
potential positive outcomes suggested by these results are unable to be fully 
interpreted with the existing data. Future research could involve both qualitative data to 
ascertain thoughts and feelings associated with this diabetes management method, 
and quantitative data on nutrient intakes and hunger levels.  
A lack of increase in TDI over 12 months is further notable as progression of β-cell 
failure in T2DM results in a tendency for insulin doses to increase over time in order to 
maintain stable glycaemic control (Holman et al., 2009). Future studies would benefit 
from including a measure of endogenous insulin production, such as serum C-peptide, 
to reduce confounding for associations of TDI.  
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Robust data regarding the change in TDI is imperative for cost effectiveness analyses 
of this management method for T2DM. Reducing TDI, even to a small degree, would 
have an economic implication. In the financial year 2011/12 more money was spent on 
drugs for diabetes than any other group of medications (Health and Social Care 
Information Centre, Prescribing and Primary Care Services, 2012). Incorporation of 
carbohydrate counting and insulin dose adjustment training into routine care for T2DM 
would only be advocated if evidence indicated not only improvements in clinical and 
psychological parameters, but a positive cost-benefit therefore this should also be a 
priority of further research. 
5.5.3 Treatment satisfaction 
Treatment satisfaction remained approximately static in Group I whilst increased 
slightly and non-significantly in Group D during the MATCH IT study. Again improved 
satisfaction with healthcare may have occurred simply as a result of participating in the 
trial and it may be that not all changes in satisfaction were able to be detected.  
Treatment satisfaction scores in both groups were high at baseline indicating a pre-
existing high degree of satisfaction and thus limiting possible improvements. The 
DTSQc questionnaire was designed to overcome this “ceiling effect” (Pouwer, Snoek, 
& Heine, 1998). Data from the DTSQc show MATCH IT resulted in a considerable 
increase in treatment satisfaction at 6 months which was not detected by the DTSQ; 
carbohydrate counting and flexible insulin dosing therefore appears to be a well- 
accepted management option for adults with T2DM. DTSQc results are not comparable 
between or within groups therefore inferential statistics were not possible. This data 
serves to substantiate the notion that changes in treatment satisfaction are not 
observed because participants are already satisfied with their treatment at baseline, 
rather than because improvements did not occur. 
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5.5.4 Vascular risk factors: BMI and waist circumference 
Vascular disease is the biggest cause of mortality and morbidity in T2DM (Roper, 
Bilous, Kelly, Unwin & Connolly, 2001). It is therefore crucial that any gains in terms of 
glycaemic control and quality of life that may be achieved with MATCH IT training in 
T2DM are not offset by deterioration in the vascular risk factors BMI, waist 
circumference, blood pressure and blood lipids. This is particularly relevant to the 
present study as insulin regimes including prandial doses of insulin are associated with 
greater weight gain than pre-mixed or basal insulin regimes (Holman et al., 2007) 
which could then induce increments in other CVD risk factors. 
In this research participants were educated in carbohydrate counting as a means of 
liberating as opposed to restricting dietary intake. Healthy eating was advocated as a 
principle throughout but no specific guidance on what constitutes healthy eating was 
provided. It is with interest that anthropometric data is here examined as adults with 
T2DM are typically prone to overweight and being overweight likely contributed to the 
development of their T2DM through insulin resistance (Taylor, 2008). This could 
suggest that allowing increased dietary freedom, by providing the means of blood 
glucose management regardless of carbohydrate intake, and the knowledge that 
dietary fat has a negligible effect on short-term glycaemic control, could result in 
exacerbation of already elevated BMI and waist circumference in this cohort, 
particularly in association with the weight gain risk of prandial insulin doses (Holman et 
al., 2009). In fact BMI and waist circumference both decreased non-significantly in the 
intervention group at 6 months. As previously discussed this could suggest that 
participants improved their eating habits, or the flexibility of the current approach 
allowed variable, and perhaps reduced, carbohydrate portions, or perhaps that reduced 
insulin doses caused weight loss. This is especially notable considering glycaemic 
control improved, a consequence of which is usually weight gain secondary to 
decreased glycosuria. 
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Unfortunately the improvement in BMI and waist circumference may have been a 
temporary consequence of participating in a research trial causing greater 
consciousness of food choices as the improvement is attenuated slightly, though still 
persists, at 12 months. On the other hand BMI and waist circumference increased 
slightly in the control group at 6 months despite participating in the study, although 
healthcare professional contact time was not matched with the intervention group. This 
could represent a lack of change in eating habits in this group due to reduced time 
spent with research staff hence less inadvertent motivation for improved eating 
behaviours, or that the continuation of rigid insulin dosing has limited weight 
maintenance. 
Regardless of the causal factors, carbohydrate counting and flexible insulin dosing 
appears to be associated with weight loss in a population group prone to obesity. 
5.5.5 Vascular risk factors: Blood pressure and blood lipids 
Blood pressure and blood lipids again represent risk factors for vascular disease and 
may have been susceptible to increases in the intervention arm of this study, both due 
to increases in body weight and to enhanced dietary freedom. Blood pressure did not 
change in Group I but decreased non-significantly in Group D over 6 months.  
Total cholesterol was increased compared to baseline in Group I at both 6 and 12 
months however this was not significant and cholesterol remained well-controlled. This 
was accompanied by a small non-significant rise in HDL cholesterol but not sufficient to 
account for the elevation in total cholesterol indicating atherogenic LDL increases were 
responsible for the overall rise in total cholesterol. Although cholesterol has not been 
shown to increase in some studies of carbohydrate counting (Bergenstal et al., 2008; 
DAFNE Study Group, 2002), one study, in line with MATCH IT demonstrated that 
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increased liberalisation of diet was associated with increased cholesterol (Mühlhauser 
et al.,1995).  
5.6 Strengths  
This proof-of-concept study was small but well-designed with appropriate methodology, 
and utilises an educational approach that would be viable in routine clinical practice. 
The use of randomisation and a control group adds valuable internal validity and 
although a limited number of participants were involved, the consistency of the results 
with comparable research, even those that did not reach statistical significance, lends 
weight to the conclusions regarding the primary outcomes reached. Data were handled 
sensitively taking sample size, skewed variables and outliers into consideration through 
the use of non-parametric tests, and medians and interquartile ranges as measures of 
centrality and dispersion. In addition external validity was good as the study population 
likely represents the target population of older adults with T2DM in Cheshire. It was 
acknowledged at the outset that this study was underpowered meaning there may be 
associations which were not able to be detected yet this does not undermine the 
statistically significant results that were established.  
5.7 Limitations 
5.7.1 Study design and sample size 
As this piece of research was carried out for a Master’s degree project it was 
constrained in duration and sample size. Firstly the small sample size necessary to 
make this study manageable results in several limitations, however it also made the 
project well suited as a pilot study. Although the small sample size limits extensive 
hypothesis testing, information has been gained from which sample sizes for future 
research in this area could be calculated. Data presented here are exploratory; the 
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study was underpowered to detect significant changes to glycaemic control and 
psychosocial outcomes and the sample size does increase the likelihood of a “type II 
error” occurring as a result of the study’s lack of power.  
The drop-out rate was also high, likely due to the demographic of the study population 
and duration of the study, further reducing the sample size such that inadequate data 
was collected at the 12 month point for Group D. Moreover the small sample size 
resulted in baseline differences between the control and intervention groups despite 
randomisation. Notable disparities included a significantly higher perceived frequency 
of hypoglycaemia, and a non-significantly lower general well-being and lower HbA1c in 
Group I. This implies Group I may have comprised more “worried well” individuals, or 
that maintaining better glycaemic control was having negative effects on well-being, 
perhaps due hypoglycaemia, and therefore Group I had more to gain in the MATCH IT 
study. In sum, the inequalities in baseline variables made results more challenging to 
interpret. 
A second limitation is that the study was only one year in duration and long-term follow-
up would be required to fully ascertain effects on biomedical and psychosocial 
parameters as similar studies acknowledge deterioration of glycaemic benefits over 
time and suggest refresher courses may be required to maintain beneficial effects of 
the interventions (Plank et al., 2004; Speight et al., 2010). Expanding the data collected 
for this study would also have enhanced its utility but was not possible. Options could 
include details of qualitative experiences during MATCH IT, 8-point glucose profiles 
and plasma C-peptide. 
It is acknowledged that detection bias will have compromised the internal validity of this 
research as it was not possible to blind either researcher or participants to their group 
allocation. This may have affected outcomes that required some degree of subjective 
interpretation, for example physical activity levels, incidence of hypoglycaemia and all 
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questionnaire answers. Additionally lack of blinding could also have attenuated the 
difference between groups as participants were informed of the nature of the study 
investigating matching insulin doses and carbohydrate intakes and therefore may have 
become more aware of their carbohydrate loads relative to their static insulin doses. 
Data collection techniques may also have contributed to decreased internal validity and 
reliability as laboratory assays are subject to low inherent error, and the method for 
assessing actual incidence of hypoglycaemia was limited due to reliance on participant 
recall, as previously discussed. Data on physical activity levels was also not as robust 
as other outcomes, relying on subjective reporting, to control for confounding.  
Finally group education for individuals using basal-bolus insulin, in the absence of 
carbohydrate and flexible insulin dose training, has been associated with improved 
HbA1c, mostly as a function of improved diabetes knowledge (Schiel, Ulbrich & Müller, 
1998) although increased diabetes knowledge is not always associated with better 
biomedical outcomes (Persell et al., 2004). In this study the disparity in health 
professional contact time and general diabetes knowledge provision between the 
intervention and control groups could have contributed to the observed results. The 
group education approach on which MATCH IT was based on has been shown to be 
effective at improving HbA1c in individuals with T1DM (DAFNE Study Group, 2002; 
Patel et al., 2010) however individuals’ learning styles vary. Some participants may 
have responded better to individual educational sessions, or to gradual rather than 
intensive education. It cannot be dismissed that a lack of significant changes in 
biomedical and psychosocial outcomes could be due to the education method rather 
than the diabetes management technique. 
5.7.2 Sample composition 
Inherent in almost any research is a selection bias arising from the inclusion of 
potentially more health-motivated participants which could exaggerate the effect of the 
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intervention studied. Similarly attrition bias may have occurred in the difference 
between study completers and those who dropped out at baseline. Results may not be 
generalisable to individuals with T2DM in other areas as the geographical area from 
which MATCH IT sampling occurred is more affluent than the UK average (Western 
Cheshire Primary Care Trust, 2007), and the sample included no heterogeneity in 
ethnic group or age. Insulin therapy choice may further limit generalisability of results. 
Most MATCH IT participants used insulin glargine or detemir as long-acting 
background insulin however in current practice many adults with T2DM newly 
commenced on a basal-bolus insulin regime will be prescribed isophane insulin. 
Systematic reviews have shown the non-inferiority of isophane insulin compared to 
over glargine and detemir in T2DM (Qayyum et al., 2008; Singh et al., 2009) and due to 
current pricing, it is advocated as a first line insulin (NICE, 2009) but its different action 
profile means MATCH IT results are not necessarily comparable. 
Individuals with T2DM represent a heterogeneous group with differences arising from 
the pathogenesis of their disease, their genotypes and phenotypes (Alsahli & Gerich, 
2010). Phenotyping of patients was not possible for this study, however it is estimated 
that approximately 15% of individuals diagnosed as T2DM are misclassified and 
actually have other types of diabetes such as late-onset autoimmune diabetes or 
mongenic diabetes (Jones & Hattersley, 2010; Wroblewski, Gottsater, Lindgarde, 
Fernlund & Sundkvist, 1998) and around another 5% have mature onset diabetes of 
the young (MODY) indicating the individuals participating in this research may have 
provided a diverse group both in terms of their endogenous insulin production, and 
possibly their classification of diabetes. Consequently data from this group was highly 
dispersed for some variables and the outliers present could not be attributed to data 
collection errors, but more likely arose from the non-homogenous population from 
which sample was taken.  
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Moreover the inclusion of individuals with medical conditions other than T2DM was 
necessary to acquire a large enough sample size and does replicate the use of 
carbohydrate counting and flexible insulin dosing in a realistic clinical population. 
However results are subject to confounding from these concomitant conditions on both 
the primary outcomes of HbA1c and QoL questionnaire results.  
5.7.2 Data analysis 
Although analysis was designed to be per-protocol by only including data from 
participants who completed the study as per the protocol, participants adherence to 
flexible insulin dosing principles were not measured therefore not all participants who 
contributed data were using this diabetes management method consistently. This could 
cause underestimation of the real biological effects of carbohydrate counting and 
insulin dose adjustment in T2DM, but does more accurately represent individuals’ 
imperfect and varying use of the technique. This also provides clinically useful 
information as individuals with T2DM are matched to insulin regimes irrespective of 
suitability for carbohydrate counting and flexible insulin dosing education and therefore 
assessing its effect as an adjunct to existing therapy is essential. An intention-to-treat 
analysis would be superior in clarifying the cost-effectiveness of a similar intervention in 
a realistic clinical situation as this would be robust against non-random participant 
attrition. However his study was concerned with the impact of MATCH IT on clinical 
and psychological parameters, rather than the practical value and cost-effectiveness of 
providing the intervention. In addition intention-to-treat analysis of the data would not 
have been possible as most participants who left the study early were either lost to 
follow up or declined to participate in further study procedures. This combined with the 
high drop-out rate for Group D rendered some data unusable, and resulted in a study 
that was in effect a 6 month randomised controlled trial with a control and intervention 
arm. 
72 
 
5.8 Significance of results   
This exploratory study indicates that MATCH IT training is feasible for adults with 
T2DM and confirms the need for a large, well-designed study to fully assess its impact. 
This study adds to the existing literature on carbohydrate counting and flexible insulin 
dosing by piloting methodology in a novel patient group and providing data suitable for 
future power calculations on the use of this management method in individuals already 
treated with basal-bolus insulin. In addition it provides data regarding the psychosocial 
impact of this intervention in T2DM which was previously unknown. This study was not 
designed to definitively answer the research questions and due to the sample size and 
study power it is not possible to conclusively accept or reject the primary hypothesis 
regarding the effect on glycaemic control, but the impact of MATCH IT on one measure 
of QoL has been ascertained to be positive. 
Extrapolating from evidence of flexible insulin dosing in T1DM and from data in this 
study, employing MATCH IT training in T2DM may have significant implications. This 
management method could improve glycaemic control and quality of life, reduce 
diabetes complications and result in more physiologically appropriate use of insulin, 
representing considerable immediate and future cost-savings to the healthcare system, 
as well as enhancing patients’ lives. Clinical gains may be negated somewhat by 
increased health professional input required to teach and sustain this management 
technique but as in T1DM, may remain cost-effective overall (NI1CE, 2003). Intensive 
education is required for the success of this method, and Diabetes Specialist Dietitians 
play a vital role in this (Delahanty, 2010). However implementation of this education 
programme with suitable individuals with T2DM may overburden dietetic resources as 
many services already fail to meet the minimum recommended number of four full-time 
Diabetes Specialist Dietitians per 250,000 head of population (Diabetes UK, 2011). It is 
also likely that sustained user support is required; this study indicates attenuation of 
glycaemic control benefits may occur within 6 months possibly due to lack of continued 
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health professional input. Similarly insulin requirements usually alter over time and, 
although taught how to adjust insulin-to-carbohydrate ratios and correction factors in 
this and similar studies, few individuals have the confidence to do so (Lawton et al., in 
press) and are therefore reliant on health professionals. Interestingly however MATCH 
IT suggests that shorter education sessions can still be effective at educating 
individuals in carbohydrate counting and insulin dose adjustment. 
MATCH IT data do not indicate a change clinical practice is warranted however the 
results suggest there no detrimental effect to clinical or psychosocial parameters arises 
from introducing flexible insulin dosing as a T2DM management method. This, in 
conjunction with its incorporation into clinical practice in some NHS services already 
(personal communication) despite lack of evidence of efficacy, demonstrates it can be 
used safely for patients struggling to integrate prandial insulin treatment with their 
lifestyle. Nevertheless this technique should not be used to pursue aggressive 
treatment goals of HbA1c <48mmol/mol whilst there is uncertainty about possible 
increased mortality in intensively treated older individuals with T2DM (ACCORD Study 
Group, 2008). The incorporation of this management method into routine clinical care 
for adults with T2DM on basal-bolus insulin will be dependent on future research into 
clinical and cost effectiveness.  
As previously acknowledged weight loss would have a significant impact on glycaemic 
control for most individuals with T2DM however it is justifiable to explore other methods 
of diabetes management as it is notoriously difficult to adhere to a weight loss plan, 
and for those individuals predisposed to β-cell failure for whom body weight is not a 
major contributor to T2DM pathogenesis. MATCH IT, whilst not aiming to elicit weight 
loss, is very acceptable from a patient perspective as the principles do not alter 
whether the individual is following a weight reduction plan or not, indeed it can be used 
in conjunction with any eating plan or pattern. It could also appeal due to the early 
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improvements in QoL for users, whereas the benefit of improved glycaemic control on 
amelioration of risk of diabetes-related complications is neither tangible nor immediate. 
Furthermore intensifying glycaemic control tends to increase body weight and 
frequency of hypoglycaemia (ACCORD Study Group, 2008; Holman et al., 2007). 
Methods such as flexible insulin dosing are vital to optimise glycaemic control without 
deterioration of BMI or increased incidence of hypoglycaemic episodes which putatively 
lessen the decrement in macrovascular risk reduction arising from good blood glucose 
regulation (Skyler et al., 2009). Therefore despite not tackling the aetiology of T2DM, 
there is clearly a place for carbohydrate counting and insulin dose adjustment in some 
individuals with T2DM. 
This flexible diabetes management method is also likely to be increasingly relevant as 
the incidence of T2DM increases in younger age groups (Vivian, 2006) exacerbating 
disease progression due to duration of diagnosis and increasing the likelihood of insulin 
therapy treatment. Unfortunately not all participants were able to use the carbohydrate 
counting and flexible insulin dosing approach in this, and similar studies (Laurenzi et 
al., 2011; Zipp, Roehr, Weiss & Filipetto, 2011). Since the commencement of the 
MATCH IT project blood glucose meters including inbuilt bolus insulin calculators and 
accompanying computer software for blood glucose pattern analysis have been 
launched. Although published evidence of their efficacy is lacking, intuitively it would 
appear that these devices could attenuate some of the issues of adherence to this 
technique such as good record-keeping and complex mental arithmetic (Lawton et al., 
in press).  As numeracy and analytical skills would no longer be a limiting factor 
preventing some individuals from successfully incorporating the technique into their 
lives, clinical effectiveness, if achievable, is likely to be attained by the majority of 
motivated users of these blood glucose meters. 
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6. Conclusion 
In conclusion MATCH IT training for adults with T2DM on a basal-bolus insulin regime 
enhanced quality of life and diminished perceived frequency of hypoglycaemia. This 
was achieved with a short group educational programme that could be realistically 
incorporated into routine clinical care. Carbohydrate counting and flexible insulin dosing 
may have improved HbA1c, even in well-controlled individuals, and is at least non-
inferior to standard insulin regimes with no observed effect on most vascular risk 
factors despite an increase in dietary freedom. It also reduced total daily insulin doses 
and resulted in less weight gain compared to standard care but sustaining all positive 
changes over 12 months may be challenging. Use of the technique may have resulted 
in a small increase in the incidence of hypoglycaemia and total cholesterol but this was 
not clinically relevant. This feasibility study confirms the viability of training in 
carbohydrate counting and insulin dose adjustment for T2DM and demonstrates the 
technique could confer a multitude of benefits for both the individual patient and the 
healthcare system in the UK.  
Overall the results of the MATCH IT study suggest a positive effect of carbohydrate 
counting and insulin dose adjustment training in adults with T2DM despite the 
limitations of this research. This management technique is worthy of further research to 
thoroughly assess its impact and a large study with an appropriate follow-up period, 
matched education time between groups, and possibly utilising bolus insulin 
calculators, is recommended. 
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Appendix 3 Researcher-administered questionnaire 
Participant Identification Number: 
 
Data collection appointment number:  1   2   3 
 
 
MATCH IT data collection tool 
 
Date of birth:     Sex: M   F 
 
Age:   Race:  
 
Date diabetes diagnosed………………………………………………………………………………………. 
 
Medical History………………………….:………………………………………………………………………… 
…………………………………………………………………………………………………………………………….. 
……………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………. 
 
Current medications and doses:………………………………………………………………………… 
…………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………… 
 
 
Inclusion/exclusion criteria checked………………………………………………………………… 
  
Weight:  kg   Waist circumference:  cm 
 
Height:  m   Blood pressure:         /       mmHg 
 
Diabetes Medication:…………………………………………………………………………………………………. 
 
Long-acting insulin………………………………………Date started month/year……………………. 
 
Range of doses given:………………………………………………………………………………………………….. 
 
Average dose given:……………………………………………………………………………………………………. 
 
 
 
 
Short-/Quick-acting insulin………………………………… Date started month/year ………….. 
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Range of doses: B’fast:….…….…Lunch:..….………….Dinner:…….…….….…Snacks:….………..… 
 
Average dose given:…………………………………………………………………………………………………….. 
 
Average total daily insulin dose:………………………………………………………………….................. 
 
 
Hypoglycaemia 
 
Episodes of mild hypoglycaemia in last month………………………………………………….. 
 
Episodes of moderate hypoglycaemia in last month……………………………………………. 
 
Episodes of severe hypoglycaemia in last month……………………………………………….. 
 
 
Lifestyle 
. 
Alcohol intake:          units/week 
 
Activity level:      Sedentary  Light    Moderate  Intense
  
 
Check Meter 
 
 
 
 
 
 
 
 
HbA1c………………………………………………………………………………………………… 
 
Total cholesterol:……………………………………………………………………………………. 
 
HDL cholesterol: ……………………………………………………………………………………. 
 
Triglycerides: ………………………………………………………………………………………… 
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Appendix 6 Participant invitation letter 
 
 
 
 
 
 
Diabetes Unit 
Countess of Chester Hospital NHS 
Foundation Trust 
Countess of Chester Hospital 
Health Park, 
Liverpool Road 
Chester CH1 2UL 
 
Date 26th November 2010 
««AddressBlock»» 
 
 
««GreetingLine»» 
 
 
Research looking at dietary freedom and flexible insulin 
dosing in type 2 diabetes: MATCH IT (MAtching Treatment to 
CarboHydrates in Insulin-treated Type 2 diabetes) 
 
 
The University of Chester and the Countess of Chester Hospital are working together to do a 
research study and are writing to you to ask if you would be willing to take part. The project 
is looking at the way people with diabetes manage their condition and is investigating a new 
way of controlling blood glucose levels by matching the insulin doses you give yourself to 
the food that you eat. This can also allow more dietary freedom. We hope this will help us 
see if more flexible treatments are possible for people with type 2 diabetes. 
 
  
Why have I been asked?  
You have been chosen because you have type 2 diabetes and take a certain type of insulin. 
You are one of a large number of people from the hospital that we are asking to help.  
 
 
What would I have to do?  
If you agree to take part, it would involve making at least three visits in one month to the 
Countess of Chester Hospital where you would receive training in a group and on a one-to-
one basis. We aim to teach you how to match the insulin you inject to the food you eat. You 
would also make three other visits over the course of a year to allow us to collect some 
information about you. The researchers would ask you some questions about your diabetes, 
give you a questionnaire to fill in and you would have your blood pressure, height and weight 
measured, and we would take a blood sample. The researchers will reimburse you for travel 
expenses for all your visits. 
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How do I reply?  
If you think you might want to know more, you can register your interest in one of these 
ways: 
 
1. You could complete the reply-slip and return it to us. A researcher will contact you 
to discuss the study.  
 
2. You can telephone 01244 366 581 and leave a message on the answer machine of 
the study dietitian, Sarah Fitzgerald, and she will return your call. Please note 
messages are not always picked up daily. 
 
If you are interested in taking part the researchers will give you more details about the study. 
By contacting us you will not be under any obligation to take part, and you will be free to 
change your mind at any time.  
 
If you are not interested in taking part in the study, we would be grateful if you could 
complete the reply-slip and we will not contact you. 
 
If you have any questions please contact Sarah Fitzgerald, the study dietitian, on 01244 366 
581. The researchers look forward to hearing from you. 
  
 
Yours sincerely, 
 
 
 
Sarah Fitzgerald 
Dietitian 
 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - -- - - - - -  
 
I am interested in knowing more about the MATCH IT study looking at dietary 
freedom and flexible insulin dosing in type 2 diabetes  
 
I am NOT interested in knowing more about the MATCH IT study looking at dietary 
freedom and flexible insulin dosing in type 2 diabetes  
 
 
My name is……………………………………………………………………………………………… 
 
The first line of my address is………………………………………………………………………… 
 
Please contact me on this telephone number……………………………………………………… 
 
Or this telephone number……………………………………………………………………………… 
 
Between the times of…………………………………………………………………………………… 
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Appendix 7 Participant information sheet 
 
 
 
 
 
Information about the Research 
 
A feasibility study of carbohydrate counting and flexible insulin dosing in 
adults with type 2 diabetes:  
MATCH IT (MAtching Treatment to CarboHydrate in Insulin-treated type 
Two diabetes) 
 
We would like to invite you to take part in our research study. Before you decide, we would like you to 
understand why the research is being done and what it would involve for you. One of our team will go 
through the information sheet with you and answer any questions you have. We‘d suggest this 
should take about 10 minutes. 
 
This copy of the information sheet is yours to keep. Should you decide to take part, a copy of the 
consent form you have signed will also be yours to keep. 
 
Talk to others about the study if you wish. Part 1 tells you the purpose of this study and what will happen 
to you if you take part. Part 2 gives you more detailed information about the conduct of the study. Ask us 
if there is anything that is not clear. 
 
Part 1. 
The study purpose 
We want to investigate a new way of controlling your blood glucose levels by matching the insulin doses 
you give yourself to the food that you eat. This has not been tested extensively in people with type 2 
diabetes but is an option in standard care for people with type 1 diabetes. 
  
By the end of this research it is hoped that you will be able to recognise the foods that affect your blood 
glucose levels, the carbohydrates, and to calculate the quantity of them that you plan to eat at each 
meal. You will then be able to calculate your exact insulin dose required for that meal. 
 
Doing this should give you freedom to eat the quantities of carbohydrate that you want, without having 
to choose standardised portions to match your prescribed insulin. Your insulin doses will be tailored to 
your diet and lifestyle rather than your diet and lifestyle fitting around your insulin doses. 
 
We plan to teach you to be able to do this in two interactive and informal group education sessions, 
each of 3 hours duration, on two consecutive weeks followed by one 30 minute appointment one-to-one 
with a dietitian. 
 
Why have I been invited? 
You have been invited because your health records identified you as a person who has had type 2 
diabetes and who injects a rapid-acting or short-acting  insulin (Novorapid, Humalog, Actrapid or 
Humulin S). 
 
Do I have to take part? 
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It is up to you to decide if you join the study. We will describe the study and go through this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at 
any time throughout the study, without giving a reason. This would not have any consequences for you, 
nor would affect the standard of care you receive and you can return to your usual insulin prescription. 
 
What will happen to me if I take part? 
This study is a pilot of a randomised trial which means we are testing a way of investigating something. 
Sometimes we don‘t know which way of treating patients is best. To find out, we need to compare 
different treatments. We put people into groups and give each group a different treatment. The results 
are compared to see if one is better. To try to make sure the groups are the same to start with, each 
participant is put into a group by chance (randomly).  
 
In our study, we want to compare your usual insulin prescription to a more flexible one, determined by 
what you eat. Everyone invited to take part in the study will have the chance to be taught how to change 
their own insulin doses. Some people will be taught this at the start of the study and some people six 
months later. This allows us to compare the people who have received the education, who are changing 
their own insulin doses, with the people who are still waiting to attend the education and using their 
usual insulin prescriptions.  
 
If you decide to take part, you will be randomised to either attend the education sessions immediately, 
or to attend them in 6 months time. You have a 50% chance of being invited to start the education 
immediately. No matter which group you are put into, we would like to collect information about you at 
the start of our study and after 6 and 12 months.  
 
To collect information, we will invite you to attend an appointment at the Countess of Chester Hospital. 
Your appointment will last approximately an hour and you will see a researcher (likely a dietitian), a 
clinic nurse and a phlebotomist, whose job it is to take blood samples.  
 
The information we would like to collect will come from a blood sample, a questionnaire you fill in, 
questions we will ask you and your height, weight, waist circumference and blood pressure. 
 
You will be involved in the study for 12 months in total. After you have attended the education sessions, 
you will hopefully know how to change your insulin doses to match the food you eat and you will go back 
to usual monitoring by diabetes healthcare professionals. If at any time, you would like to see a 
healthcare professional about what you have been taught as part of this research, you can contact us.  
 
Expenses 
As a thank you for taking time to take part in our study, we will offer you the chance to claim back the 
cost of travelling to the hospital and parking, if applicable, up to £5 each way. 
 
What will I have to do? 
If you decide to take part in the study, please be sure you can commit to attending the three 
appointments, during which we will gather information about you, and the two group education sessions, 
each of three hours duration, plus a one hour appointment with the dietitian. This makes six visits to the 
Countess of Chester Hospital in total. 
 
After the first education session we will ask you to monitor your blood glucose levels at home more often 
than you may do now, and to write this down, together with the amount of carbohydrate that you eat, 
and the insulin dose that you give yourself. We will give you a diary to enable you to do this. This helps 
us personalise the information we give you at the second group education session. 
  
Throughout this study, we ask that you continue to take your usual medication at your usual times.  We 
will only teach you to change the amount of insulin that you give yourself, all other doses of your 
medications should remain as your doctor has prescribed them. 
 
What are the possible disadvantages and risks of taking part? 
The disadvantage of taking part is the amount of time we will take to gather information from you and to 
teach you how to match your insulin doses to your food. It may be an inconvenience to you to attend 
these appointments and education sessions. 
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The blood sample we will take will be no different than a normal blood sample requested by your doctor 
so this should be no more uncomfortable than usual. We will ask that you monitor your blood glucose 
levels more often at home and doing this can sometimes cause sore fingers. 
 
There is a risk that you may have more episodes of hypoglycaemia (low blood glucose levels) than 
usual. As part of the education we will discuss how to avoid, identify and treat hypoglycaemia. There is 
also a risk that you may gain weight. This is because we are showing you how to increase your dietary 
freedom whilst keeping your blood glucose levels close to the normal range so you will be able to eat 
whatever you choose. This could include high-fat, high-sugar foods you may have previously avoided. If 
you eat more calories than you need in a day, you will gain weight, just as someone without diabetes 
would. The education is not about healthy eating but we would still encourage a balanced diet. On the 
other hand, it is possible to use this education to reduce the amount you eat, without a greater risk of 
hypoglycaemia, and this can help with weight loss. 
 
What are the side effects of any treatment received when taking part? 
There will be no side effects due only to taking part in this research. The side effects of taking insulin will 
remain the same and these should be discussed with your doctor if required. 
 
Harm to the unborn child  
There should be no harm to an unborn child as a result of changing insulin doses to match the food you 
eat, however pregnant women are not eligible to take part in this study. If you were to become pregnant, 
you should inform the study researcher and your doctor immediately. 
 
What are the possible benefits of taking part? 
We cannot promise this study will help you but the information we get from this study may help improve 
the treatment of people with type 2 diabetes. 
 
This study may give you a greater understanding of your diabetes and how the food you eat, in 
particular the carbohydrates, affects your blood glucose levels. It may give you the knowledge and 
confidence to change your insulin doses based on what you are eating, which can change day-to-day 
and meal-to-meal, rather than injecting your prescribed insulin dose. 
 
Doing this should give you freedom to eat the quantities of carbohydrate that you want, without having 
to choose portions to match your prescribed insulin. Your insulin doses will be tailored to your diet and 
lifestyle, rather than your diet and lifestyle fitting around your insulin doses.  
 
This does not mean that we no longer recommend eating a healthy balanced diet but this method allows 
you to have more flexibility in your diet while still being able to keep your blood glucose levels well 
controlled. In fact, after this study, you may find your blood glucose levels improve because you are 
giving yourself more personalised insulin doses and this could reduce the risk of you developing 
diabetes-related health problems such as damage to your heart, kidneys and eyes. 
 
This completes Part 1. If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any decision. 
 
Part 2. 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, your research 
doctor will tell you and discuss whether you should continue in the study. If you decide not to carry on, 
your research doctor will make arrangements for your care to continue. If you decide to continue in the 
study he/she may ask you to sign an agreement outlining the discussion. 
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw at any time throughout the study, without giving a reason. This would not have 
any consequences for you nor would it affect the standard of care you receive and you can return to 
your usual insulin prescription if you wish. 
 
You can withdraw from the study but still keep in contact with us to let us know your progress. 
Information collected may still be used unless you tell us not to. If you wish to completely withdraw from 
the study, we may continue to use the data we have already collected from you, unless you tell us not 
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to. At any point in the study, and up until we analyse our data, you have the right to ask us to destroy 
the data that we hold on you and not include it in our study results. 
 
 
What if I have a complaint? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher who will 
do her best to answer your questions. Please contact Sarah Fitzgerald, Dietitian on 01244 366 581. If 
you remain unhappy, or do not want to speak to a researcher, and wish to complain formally about this 
study, you can do this through the University of Chester complaints procedure by writing to the Dean of 
Applied and Health Sciences, Professor Sarah Andrew. Further details can be obtained from the 
University of Chester on 01244 511000. 
 
Alternatively, if you wish to make a complaint regarding the standard of healthcare you have received, 
please contact PALS, the Countess of Chester Hospital Patient Advice and Liaison Service. You can 
phone the PALS manager on 01244 366066. To make a formal complaint, you can also write to the 
Chief Executive of the Trust, Peter Herring. 
 
What if something goes wrong? 
In the unlikely event that something does go wrong and you are harmed during the research and this is 
due to someone‘s negligence then you may have grounds for a legal action for compensation against 
the University of Chester or the Countess of Chester Hospital NHS Foundation Trust, but you may have 
to pay your legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential, and any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised. You can ask to see the data we hold on you, to check it for 
errors. 
 
Your data will be stored on a computer database, but your details will be coded so that it will not be 
possible to identify you from the data we hold on the database. We will have a paper hard copy of your 
personal details, together with your code, which will identify data as yours should we need to do this. 
This will be secured in a locked drawer, in a locked room at all times not in use, and only authorised 
researchers will have access to your identifiable data. A password-protected electronic copy of this will 
be stored on an NHS computer network with a password protected log-in so it will not be possible for 
others to find out your identity from your coded data. 
 
Your coded data will be kept securely for 10 years then destroyed confidentially. The data you provide 
may be used in the future, but it will not be possible for others to find out your identity from your coded 
data in the future. You need to inform us if you do not wish your anonymous data to be used in future 
research. 
 
Involvement of the General Practitioner (GP) 
A diabetes consultant at the Countess of Chester Hospital will have assessed you for eligibility before 
we invited you to take part in this research. He will also be notified that you have agreed to take part if 
you decide to. Once you have completed the education sessions as part of this research, we will write to 
your GP to let them know that you have attended this course and that you may now wish to change your 
own insulin doses. 
 
What will happen to any samples I give? 
You will be asked to give blood samples specifically for the purpose of monitoring the effect of this 
study. These blood samples will be destroyed in line with Countess of Chester Hospital policy and will 
not be retained for the purpose of this study. The results of your blood tests will be available on our 
hospital database so any healthcare professional involved in your care can view them. 
 
What will happen to the results of the research study? 
Your individual results indicating your blood glucose control and cholesterol levels from blood samples 
collected at the start of the study, at 6 months and at 12 months will be shared with you by letter. 
 
121 
 
The broader findings from our research will hopefully be published in a scientific journal and/or 
presented at a conference. You will not be identified in any publication or presentation. A summary of 
our research findings will be shared by letter with all the people who took part in the research. 
 
Who is organising and funding the research? 
The research is being carried out in part by Sarah Fitzgerald, Dietitian, as part of a study for a Masters 
degree in Nutrition and Dietetics. 
 
The University of Chester and the Countess of Chester Hospital NHS Foundation Trust are sponsoring 
the research. Funding applications are in progress but no funding has yet been secured. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
North West England Strategic Health Authority Research Ethics Committee. 
 
Further information and contact details 
For general information on research, see the Diabetes UK website, the Medical Research Council 
website or the NHS Choices websites. 
 www.diabetes.org.uk/Research 
www.nhs.uk/conditions/clinical-trials 
www.ctu.mrc.ac.uk/TakePart 
 
For specific information on this study, or advice regarding whether to participate, contact Sarah 
Fitzgerald, Dietitian on 01244 366 581. Your GP can also advise you about participating in this study.  
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Appendix 8 Participant consent form 
 
 
Participant Identification Number:  
 
CONSENT FORM 
 
 
A feasibility study of carbohydrate counting and flexible insulin dosing in adults 
with type 2 diabetes:  
MATCH IT (MAtching Treatment to CarboHydrate in Insulin-treated type Two 
diabetes) 
 
 
Name of Researcher: Sarah Fitzgerald    Please initial box  
  
1. I confirm that I have read and understand the information sheet dated 2.2.11 version 4 
for the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected. 
  
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the University of Chester, from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study.  
 
 
5. I agree to take part in the above study.  
 
 
Name of Participant:        Date:  
 
Signature: 
 
 
Name of Person taking consent:       Date: 
 
Signature:  
 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes. 
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Appendix 9 Carbohydrate counting and insulin dose 
adjustment calculations 
Calculating insulin-to-carbohydrate ratios and correction factors 
Estimates of personalised insulin-to-carbohydrate ratios and correction factors were 
calculated from participants’ blood glucose and food diaries then further adjusted as 
required based on blood glucose monitoring feedback. Insulin-to-carbohydrate ratios 
and correction factors may vary at different times of the day. 
 
Insulin-to-carbohydrate portion (insulin:CP) ratio =  
 Carbohydrate consumed (carbohydrate portions or CPs) 
                                                                     Insulin dose (units) 
 
Correction factor =                            100 
     Total daily dose of insulin (units) 
 
 
Calculating meal-time insulin doses 
Meal-time insulin dose =  
Insulin:CP ratio x CPs +  
(Δ blood glucose level to achieve pre-meal target x correction factor) + 
 % increase or decrease for physical activity/stress/illness 
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Appendix 10 GP information letter 
 
 
 
A feasibility study of carbohydrate counting and flexible insulin in people with type 2 diabetes: 
MATCH IT (MAtching Treatment to CarboHydrate in Insulin-treated type Two diabetes) 
 
 
Diabetes Centre (OPD 3) 
Countess of Chester Hospital NHS 
Foundation Trust, 
Countess of Chester Hospital Health 
Park, 
Liverpool Road, 
Chester, 
CH1 2UL 
 
Date 
 
Dear Dr (GP name), 
 
Patient name:      Date of birth: 
Address: 
Hospital number: 
 
Your patient has agreed to take part in a feasibility study. The research is investigating the effect of 
an educational intervention promoting flexibility of insulin doses and dietary freedom in people with 
type 2 diabetes on rapid- or short-acting insulin. The project will trial methodology designed to assess 
the impact of carbohydrate counting and insulin dose adjustment on quality of life, satisfaction with 
treatment and glycaemic control. This project involves a delayed start method and aims to compare 
standard care (the delayed start group prior to the intervention) to the effect of the educational 
intervention. This patient has been allocated to the: 
 
Immediate start group commencing education shortly 
 
 
Delayed start group commencing education 6 months after baseline 
 
  
As part of the study the patient will be taught to adjust their own insulin doses in relation to dietary 
carbohydrate intake. The patient will be attending the Countess of Chester Hospital for one follow-up 
appointment after the education and will then return to standard care. The patient can contact the 
researchers at any time for additional support if required.  
 
We would be very grateful if you would continue to prescribe and monitor all their medication, 
including their insulin, as before. Please do not hesitate to contact the study dietitian, Sarah 
Fitzgerald, on 01244 366 581 if you have any queries.  
 
Yours sincerely, 
 
 
Sarah Fitzgerald 
Dietitian 
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Appendix 11 Normality tests and graphs 
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